Full listing of articles published by VHIO investigators in 2019
Articles published by VHIO Investigators in 2019 with allocated Impact Factor (IF):
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D; CARD Investigators. 2019. N Engl J Med. 381(26): 2506 - 2518. IF:70,670.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Kappeler C; Snapir A; Sarapohja T; Smith MR; ARAMIS Investigators. 2019. N Engl J Med. 380(13): 1235 - 1246. IF:70,670.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J. 2019. N Engl J Med. 381(17): 1632 - 1643. IF:70,670.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O’Hagan A; Avadhani A; Siefker-Radtke AO; BLC2001 Study Group. 2019. N Engl J Med. 381(4): 338 - 348. IF:70,670.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O’Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL. 2019. N Engl J Med. 381(4): 317 - 327. IF:70,670.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O’Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. 2019. N Engl J Med. 381(25): 2391 - 2402. IF:70,670.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA. 2019. N Engl J Med. 381(25): 2403 - 2415. IF:70,670.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ; IMmotion151 Study Group. 2019. Lancet. 393(10189): 2404 - 2415. IF:59,102.
Cervical cancer. Cohen PA; Jhingran A; Oaknin A; Denny L. 2019. Lancet. 393(10167): 169 - 182. IF:59,102.
Actively personalized vaccination trial for newly diagnosed glioblastoma. Hilf N; Kuttruff-Coqui S; Frenzel K; Bukur V; Stevanovic S; Gouttefangeas C; Platten M; Tabatabai G; Dutoit V; van der Burg SH; Thor Straten P; Martínez-Ricarte F; Ponsati B; Okada H; Lassen U; Admon A; Ottensmeier CH; Ulges A; Kreiter S; von Deimling A; Skardelly M; Migliorini D; Kroep JR; Idorn M; Rodon J; et al. 2019. Nature. 565(7738): 240 - 245. IF:43,070.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F; IMblaze370 Investigators. 2019. Lancet Oncol. 20(6): 849 - 861. IF:35,386.
ESMO-MCBS: setting the record straight. Cherny NI; Tabernero J; de Vries EGE. 2019. Lancet Oncol. 20(4): 192 - 192. IF:35,386.
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2-3, randomised, controlled trial.Bonvalot S; Rutkowski PL; Thariat J; Carrère S; Ducassou A; Sunyach MP; Agoston P; Hong A; Mervoyer A; Rastrelli M; Moreno V; Li RK; Tiangco B; Herraez AC; Gronchi A; Mangel L; Sy-Ortin T; Hohenberger P; de Baère T; Le Cesne A; Helfre S; Saada-Bouzid E; Borkowska A; Anghel R; Co A; Gebhart M; Kantor G; Montero A; Loong HH; Vergés R; et al... 2019. Lancet Oncol. 20(8): 1148 - 1159. IF:35,386.
PET or MRI to improve response evaluation in clinical trials? Deroose CM; Gheysens O; Perez-Lopez R. 2019. Lancet Oncol. 20(8): 1060 - 1062. IF:35,386.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I. 2019. Lancet Oncol. 20(8): 1109 - 1123. IF:35,386.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA; RAINFALL Study Group. 2019. Lancet Oncol. 20(3): 420 - 435. IF:35,386.
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M. 2019. Lancet Oncol. 20(10): 1454 - 1466. IF: 35,386.
Shortages of inexpensive essential medicines. Vyas M; de Vries EGE; Casali PG; Tabernero J. 2019. Lancet Oncol. 20(5): 224 - 225. IF:35,386.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E. 2019. Lancet Oncol. 20(9): 1226 - 1238. IF:35,386.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P. 2019. Lancet Oncol. 20(8): 1124 - 1135. IF:35,386.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Vergote I; Scambia G; O’Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. 2019. Lancet Oncol. 20(6): 862 - 876. IF:35,386.
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F. 2019. Lancet Oncol. 20(12): 1702 - 1709. IF:35,386.
Chronic lymphocytic leukaemia: from genetics to treatment. Bosch F; Dalla-Favera R. 2019. Nat Rev Clin Oncol. 16(11): 684 - 701. IF:34,106.
Breast cancer. Harbeck N; Penault-Llorca F; Cortes J; Gnant M; Houssami N; Poortmans P; Ruddy K; Tsang J; Cardoso F. 2019. Nat Rev Dis Primers. 5: 66. IF:32,274.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Powles T; Kockx M; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Szabados B; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; van Dam PJ; Stanoeva D; Daelemans S; Mariathasan S; Tea JS; Mousa K; Banchereau R; Castellano D. 2019. Nat Med. 25(11): 1706 - 1706. IF:30,641.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Rodon J; Soria JC; Berger R; Miller WH; Rubin E; Kugel A; Tsimberidou A; Saintigny P; Ackerstein A; Braña I; Loriot Y; Afshar M; Miller V; Wunder F; Bresson C; Martini JF; Raynaud J; Mendelsohn J; Batist G; Onn A; Tabernero J; Schilsky RL; Lazar V; Lee JJ; Kurzrock R. 2019. Nat Med. 25(5): 751 - 751. IF:30,641.
Looking forward 25 years: the future of medicine. Regev A; Zhang F; Jaffee E; Farrar J; Nkengasong J; Topol E; Partridge L; Mundel T; Tabernero J; Sabeti P; Torreele E. 2019. Nat Med. 25(12): 1804 - 1807. IF:30,641.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF. 2019. J Clin Oncol. 37(16): 1370 - 1370. IF:28,349.
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J. 2019. J Clin Oncol. 37(17): 1460 - 1460. IF:28,349.
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL. 2019. J Clin Oncol. 37(4): 336 - 336. IF:28,349.
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R. 2019. J Clin Oncol. 37(28): 2518 - 2518. IF:28,349.
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. Fennell D A; Baas P; Taylor P; Nowak A K; Gilligan D; Nakano T; Pachter J A; Weaver D T; Scherpereel A; Pavlakis N; van Meerbeeck J P; Cedres S; Nolan L; Kindler H; Aerts J G J V. 2019. J Clin Oncol. 37(10): 790 - 790. IF:28,349.
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ. 2019. J Clin Oncol. 37(25): 2257 - 2257. IF:28,349.
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G. 2019. J Clin Oncol. 37(5): 367 - 367. IF:28,349.
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M. 2019. J Clin Oncol. 37(3): 230 - 230. IF:28,349.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Gulley JL; Borre M; Vogelzang NJ; Ng S; Agarwal N; Parker CC; Pook DW; Rathenborg P; Flaig TW; Carles J; Saad F; Shore ND; Chen L; Heery CR; Gerritsen WR; Priou F; Langkilde NC; Novikov A; Kantoff PW. 2019. J Clin Oncol. 37(13): 1051 - 1051. IF:28,349.
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R. 2019. J Clin Oncol. 37(28): 2571 - 2571. IF:28,349.
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; et al. 2019. J Clin Oncol. 37(6): 490 - 490. IF:28,349.
Reply to I. Pecora et al. Macarulla T; Hidalgo M. 2019. J Clin Oncol. 37(22): 1979 - 1979. IF:28,349.
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN. 2019. J Clin Oncol. 37(31): 2825 - 2825. IF:28,349.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O’Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM. 2019. Cancer Discov. 9(2): 210 - 219. IF:26,370.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; et al. 2019. Cancer Discov. 9(12): 1696 - 1707. IF:26,370.
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 + T Cells. Etxeberria I; Bolaños E; Quetglas JI; Gros A; Villanueva A; Palomero J; Sánchez-Paulete AR; Piulats JM; Matias-Guiu X; Olivera I; Ochoa MC; Labiano S; Garasa S; Rodriguez I; Vidal A; Mancheño U; Hervás-Stubbs S; Azpilikueta A; Otano I; Aznar MA; Sanmamed MF; Inogés S; Berraondo P; Teijeira Á; Melero I. 2019. Cancer Cell. 36(6): 613 - 613. IF:23,916.
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS. 2019. Lancet Respir Med. 7(7): 569 - 580. IF:22,992.
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leigh N B; Hellmann M D; Hui R; Carcereny E; Felip E; Ahn M-J; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB. 2019. Lancet Respir Med. 7(4): 347 - 357. IF:22,992.
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial. Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS. 2019. JAMA Oncol. 5(2): e184475. IF:22,416.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. Fernández-Martos C; Pericay C; Losa F; García-Carbonero R; Layos L; Rodríguez-Salas N; Martin-Richard M; Alonso-Orduña V; Vera R; Gallego J; Capdevila J; Salud A; Nogué M; Maurel J; Guash I; Montagut C; Lopez C; Macias I; Jain RK; Garcia-Albeniz X. 2019. JAMA Oncol. 5(11): 1566 - 1573. IF:22,416.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer The MANTA Phase 2 Randomized Clinical Trial. Schmid P; Zaiss M; Harper-Wynne C; Ferreira M; Dubey S; Chan S; Makris A; Nemsadze G; Brunt AM; Kuemmel S; Ruiz I; Perelló A; Kendall A; Brown J; Kristeleit H; Conibear J; Saura C; Grenier J; Máhr K; Schenker M; Sohn J; Lee KS; Shepherd CJ; Oelmann E; Sarker SJ; Prendergast A; Marosics P; Moosa A; Lawrence C; Coetzee C; Mousa K; Cortés J. 2019. JAMA Oncol. 5(11): 1556 - 1563. IF:22,416.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study. Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O’Hear C; Fassò M; Molinero L; Schmid P. 2019. JAMA Oncol. 5(1): 74 - 82. IF:22,416.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial. Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J. 2019. JAMA Oncol. 5(2): 195 - 203. IF:22,416.
Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? Riveiro-Barciela M; Muñoz-Couselo E; Fernandez-Sojo J; Diaz-Mejia N; Parra-López R; Buti M. 2019. J HEPATOL. 70(3): 564 - 566. IF:18,946.
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Janin M; Ortiz-Barahona V; de Moura MC; Martínez-Cardús A; Llinàs-Arias P; Soler M; Nachmani D; Pelletier J; Schumann U; Calleja-Cervantes ME; Moran S; Guil S; Bueno-Costa A; Piñeyro D; Perez-Salvia M; Rosselló-Tortella M; Piqué L; Bech-Serra JJ; De La Torre C; Vidal A; Martínez-Iniesta M; Martín-Tejera JF; Villanueva A; Arias A; Cuartas I; Aransay AM; La Madrid AM; Carcaboso AM; Santa-Maria V; Mora J; Fernandez AF; Fraga MF; Aldecoa I; Pedrosa L; Graus F; Vidal N; Martínez-Soler F; Tortosa A; Carrato C; Balañá C; Boudreau MW; Hergenrother PJ; Kötter P; Entian KD; Hench J; Frank S; Mansouri S; Zadeh G; Dans PD; Orozco M; Thomas G; Blanco S; Seoane J; et al. 2019. ACTA NEUROPATHOL. 138(6): 1053 - 1074. IF:18,174.
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS. 2019. EUR UROL. 76(5): 676 - 685. IF:17,298.
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Zafeiriou Z; Bianchini D; Chandler R; Rescigno P; Yuan W; Carreira S; Barrero M; Petremolo A; Miranda S; Riisnaes R; Rodrigues DN; Gurel B; Sumanasuriya S; Paschalis A; Sharp A; Mateo J; Tunariu N; Chinnaiyan AM; Pritchard CC; Kelly K; de Bono JS. 2019. EUR UROL. 75(1): 184 - 192. IF:17,298.
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O’Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; et al. 2019. EUR UROL. 76(6): 831 - 842. IF:17,298.
Managing Nonmetastatic Castration-resistant Prostate Cancer. Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS. 2019. EUR UROL. 75(2): 285 - 293. IF:17,298.
PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. Mateo J; Carreira S; de Bono JS. 2019. EUR UROL. 76(4): 459 - 460. IF:17,298.
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; et al. 2019. EUR UROL. 75(3): 368 - 373. IF:17,298.
Towards a New Classification for Metastatic Prostate Cancer. Mateo J; Carles J. 2019. EUR UROL. 75(3): 383 - 384. IF:17,298.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L. 2019. Sci Transl Med. 11(484): eaar5012. IF:17,200.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J. 2019. Blood. 134(16): 1337 - 1345. IF:16,601.
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; NguyenKhac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; et al. 2019. Blood. 133(11): 1205 - 1216. IF:16,601.
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Schuster SJ; Bartlett NL; Assouline S; Yoon S-S; Bosch F; Sehn LH; Cheah CY; Shadman M; Gregory G P; Ku M; Wei MC; Yin S; Kwan A; Yousefi K; Hernandez G; Li C-C; O’Hear C; Budde LE. 2019. Blood. 134(1): 6 - 6. IF:16,601.
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Garmendia I; Pajares M J; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba I I; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga L M; Agorreta J. 2019. Am J Respir Crit Care Med. 200(7): 888 - 899. IF:16,494.
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Pesarrodona M; Jauset T; Díaz-Riascos ZV; Sánchez-Chardi A; Beaulieu ME; Seras-Franzoso J; Sánchez-García L; Baltà-Foix R; Mancilla S; Fernández Y; Rinas U; Schwartz S; Soucek L; Villaverde A; Abasolo I; Vázquez E. 2019. Adv Sci (Weinh). 6(18): 1900849 - 1900849. IF:15,804.
Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory? Riveiro-Barciela M; Gironella M; Senín A; Salcedo MT; Merino-Casabiel X; Castells L; Esteban R; Buti M; Martínez-Valle F. 2019. Hepatology. 69(6): 2701 - 2703. IF:14,971.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer. Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R. 2019. Ann Oncol. 30(6): 927 - 933. IF:14,196.
A decade of clinical development of PARP inhibitors in perspective. Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS. 2019. Ann Oncol. 30(9): 1437 - 1447. IF:14,196.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Matulonis UA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Katchar K; Wu H; Keefe S; Ruman J; Ledermann JA. 2019. Ann Oncol. 30(7): 1080 - 1087. IF:14,196.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner N C; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M. 2019. Ann Oncol. 30(5): 774 - 780. IF:14,196.
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Yoshino T; Portnoy DC; Obermannová R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; García-Alfonso P; Cohn AL; Van Cutsem E; Yamazaki K; Lonardi S; Muro K; Kim TW; Yamaguchi K; Grothey A; O’Connor J; Taieb J; Wijayawardana SR; Hozak RR; Nasroulah F; Tabernero J. 2019. Ann Oncol. 30(1): 124 - 131. IF:14,196.
Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Seoane J; De Mattos-Arruda L; Le Rhun E; Bardelli A; Weller M. 2019. Ann Oncol. 30(2): 211 - 218. IF:14,196.
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L. 2019. Ann Oncol. 30(2): 290 - 296. IF:14,196.
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner NC. 2019. Ann Oncol. 30(6): 945 - 952. IF:14,196.
Efficacy of PI3K inhibitors in advanced breast cancer. Verret B; Cortes J; Bachelot T; Andre F; Arnedos M. 2019. Ann Oncol. Dec;30 Suppl 10:x12-x20. IF:14,196.
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ. 2019. Ann Oncol. 30(8): 1289 - 1297. IF:14,196.
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC. 2019. Ann Oncol. 30(3): 365 - 373. IF:14,196.
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Hammel P; Kindler HL; Reni M; Cutsem EV; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O’Reilly EM; McGuinness D; Cui K Y; Joo S; Yoo HK; Patel N; Golan T. 2019. Ann Oncol. 30(12): 1959 - 1968. IF:14,196.
Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N; Moreira L; Carneiro F; Balaguer F; Cervantes A; Balmaña J; Martinelli E. 2019. Ann Oncol. 30(10): 1558 - 1571. IF:14,196.
How liquid biopsies can change clinical practice in oncology. Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu L L; Bardelli A. 2019. Ann Oncol. 30(10): 1580 - 1590. IF:14,196.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazières J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai A A; Mascaux C; Couraud S; Veillon R; Van Den Heuvel M; Neal J; Peled N; Früh M; Ng T L; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez A; et al. 2019. Ann Oncol. 30(8): 1321 - 1328. IF:14,196.
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. Ros J; Matos I; Martin-Liberal J. 2019. Ann Oncol. 30(7): 1173 - 1177. IF:14,196.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K; Van Cutsem E; Narita Y; Pentheroudakis G; Baba E; Li J; Ryu MH; Zamaniah WIW; Yong WP; Yeh KH; Kato K; Lu Z; Cho B C; Nor I M; Ng M; Chen LT; Nakajima TE; Shitara K; Kawakami H; Tsushima T; Yoshino T; Lordick F; Martinelli E; Smyth EC; Arnold D; Minami H; Tabernero J; Douillard JY. 2019. Ann Oncol. 30(1): 19 - 33. IF:14,196.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K; Lordick F; Tsushima T; Pentheroudakis G; Baba E; Lu Z; Cho BC; Nor IM; Ng M; Chen LT; Kato K; Li J; Ryu MH; Zamaniah WIW; Yong WP; Yeh KH; Nakajima TE; Shitara K; Kawakami H; Narita Y; Yoshino T; Van Cutsem E; Martinelli E; Smyth EC; Arnold D; Minami H; Tabernero J; Douillard JY. 2019. Ann Oncol. 30(1): 34 - 43. IF:14,196.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Adams S; Schmid P; Rugo HS; Winer EP; Loirat D; Awada A; Cescon DW; Iwata H; Campone M; Nanda R; Hui R; Curigliano G; Toppmeyer D; O’Shaughnessy J; Loi S; Paluch-Shimon S; Tan AR; Card D; Zhao J; Karantza V; Cortés J. 2019. Ann Oncol. 30(3): 397 - 404. IF:14,196.
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E. 2019. Ann Oncol. 30(5): 796 - 803. IF:14,196.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Peters S; Dafni U; Boyer M; De Ruysscher D; Faivre-Finn C; Felip E; Garrido P; Girard N; Guckenberger M; Haanen J; Le Pechoux C; Mornex F; Ozsahin M; Paz-Ares L; Planchard D; Raben D; Ramalingam S; Reck M; Smit E; Stahel R; Stenzinger A; Swanton C; Vallone S; Garassino MC. 2019. Ann Oncol. 30(2): 161 - 165. IF:14,196.
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Sveen A; Cremolini C; Dienstmann R. 2019. Ann Oncol. 30(11): 1682 - 1685. IF:14,196.
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J. 2019. Ann Oncol. 30(10): 1622 - 1629. IF:14,196.
Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager? Saura C. 2019. Ann Oncol. 30(10): 1 - 2. IF:14,196.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Serrano C; Cortés J; De Mattos-Arruda L; Bellet M; Gómez P; Saura C; Pérez J; Vidal M; Muñoz-Couselo E; Carreras MJ; Sánchez-Ollé G; Tabernero J; Baselga J; Di Cosimo S. 2019. Ann Oncol. 30(7): 1178 - 1178. IF:14,196.
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C. 2019. Ann Oncol. 30(3): 439 - 446. IF:14,196.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB. 2019. Ann Oncol. 30(2): 281 - 289. IF:14,196.
Value assessment frameworks in oncology: championing concordance through shared standards. Bertagnolli M; Tabernero J. 2019. Ann Oncol. 30(4): 505 - 506. IF:14,196.
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Remon J; Ahn MJ; Girard N; Johnson M; Kim DW; Lopes G; Pillai RN; Solomon B; Villacampa G; Zhou Q. 2019. J Thorac Oncol. 14(7): 1134 - 1155. IF:12,460.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasag B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S. 2019. J Thorac Oncol. 14(6): 1086 - 1094. IF:12,460.
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; et al. 2019. J Thorac Oncol. 14(12): 2120 - 2132. IF:12,460.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS. 2019. J Thorac Oncol. 14(5): 793 - 801. IF:12,460.
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH J r, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. 2019. J Thorac Oncol. Epub 2019 Dec 20. PMID: 31870883. IF:12,460.
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer. Bauer TM; Besse B; Martinez-Marti A; Trigo JM; Moreno V; Garrido P; Ferron-Brady G; Wu Y; Park J; Collingwood T; Kruger RG; Mohammad HP; Ballas MS; Dhar A; Govindan R. 2019. J Thorac Oncol. 14(10): 1828 - 1838. IF:12,460.
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; et al. 2019. J Thorac Oncol. 14(7): 1266 - 1276. IF:12,460.
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA. 2019. J Clin Invest. 129(11): 4992 - 5004. IF:12,282.
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D; EINSTEIN-Jr Phase 2 Investigators. 2019. Lancet Haematol. 6(10): 500 - 509. IF:11,990.
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yagci M; et al. 2019. Lancet Haematol. 6(2): 67 - 78. IF:11,990.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Wang Y; Bernhardy AJ; Nacson J; Krais JJ; Tan Y F; Nicolas E; Radke MR; Handorf E; Llop-Guevara A; Balmaña J; Swisher EM; Serra V; Peri S; Johnson N. 2019. Nat Commun. 10: 5661 - 5661. IF:11,878.
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Ferreira MA; Gamazon ER; Al-Ejeh F; Aittomäki K; Andrulis IL; Anton-Culver H; Arason A; Arndt V; Aronson KJ; Arun BK; Asseryanis E; Azzollini J; Balmaña J; Barnes DR; Barrowdale D; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bialkowska K; Blomqvist C; Bogdanova NV; Bojesen SE; Bolla MK; Borg A; Brauch H; Brenner H; Broeks A; Burwinkel B; Caldés T; Caligo MA; Campa D; Campbell I; Canzian F; Carter J; Carter BD; Castelao JE; Chang-Claude J; Chanock SJ; Christiansen H; Chung WK; Claes KBM; Clarke CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; de la Hoya M; Dennis J; Devilee P; Diez O; et al. 2019. Nat Commun. 10(1): 1741 - 1741. IF:11,878.
Identification and characterization of Cardiac Glycosides as senolytic compounds. Triana-Martínez F; Picallos-Rabina P; Da Silva-Álvarez S; Pietrocola F; Llanos S; Rodilla V; Soprano E; Pedrosa P; Ferreirós A; Barradas M; Hernández-González F; Lalinde M; Prats N; Bernadó C; González P; Gómez M; Ikonomopoulou MP; Fernández-Marcos PJ; García-Caballero T; Del Pino P; Arribas J; Vidal A; González-Barcia M; Serrano M; Loza MI; Domínguez E; Collado M. 2019. Nat Commun. 10(1): 4731 - 4731. IF:11,878.
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Pascual-García M; Bonfill-Teixidor E; Planas-Rigol E; Rubio-Perez C; Iurlaro R; Arias A; Cuartas I; Sala-Hojman A; Escudero L; Martínez-Ricarte F; Huber-Ruano I; Nuciforo P; Pedrosa L; Marques C; Braña I; Garralda E; Vieito M; Squatrito M; Pineda E; Graus F; Espejo C; Sahuquillo J; Tabernero J; Seoane J. 2019. Nat Commun. 10: 2416 - 2416. IF:11,878.
Shared heritability and functional enrichment across six solid cancers. Jiang X; Finucane HK; Schumacher FR; Schmit SL; Tyrer JP; Han Y; Michailidou K; Lesseur C; Kuchenbaecker KB; Dennis J; Conti DV; Casey G; Gaudet MM; Huyghe JR; Albanes D; Aldrich MC; Andrew AS; Andrulis IL; Anton-Culver H; Antoniou AC; Antonenkova NN; Arnold SM; Aronson KJ; Arun BK; Bandera EV; Barkardottir RB; Barnes DR; Batra J; Beckmann MW; Benitez J; Benlloch S; Berchuck A; Berndt SI; Bickeböller H; Bien SA; Blomqvist C; Boccia S; Bogdanova NV; Bojesen SE; Bolla MK; Brauch H; Brenner H; Brenton JD; Brook MN; Brunet J; Brunnström H; Buchanan DD; Burwinkel B; Butzow R; Cadoni G; Caldés T; Caligo MA; Campbell I; Campbell PT; Cancel-Tassin G; Cannon-Albright L; Campa D; Caporaso N; Carvalho AL; Chan AT; Chang-Claude J; Chanock SJ; Chen C; Christiani DC; Claes KBM; Claessens F; Clements J; Collée JM; Correa MC; Couch FJ; Cox A; Cunningham JM; Cybulski C; Czene K; Daly MB; deFazio A; Devilee P; Diez O; et al. 2019. Nat Commun. 10(1): 431 - 431. IF:11,878.
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Gao M; Callari M; Beddowes E; Sammut SJ; Grzelak M; Biggs H; Jones L; Boumertit A; Linn SC; Cortes J; Oliveira M; Baird R; Chin SF; Caldas C. 2019. Genome Med. 11(1): 1 - 1. IF:10,886.
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Qian F; Wang S; Mitchell J; McGuffog L; Barrowdale D; Leslie G; Oosterwijk JC; Chung WK; Evans DG; Engel C; Kast K; Aalfs CM; Adank MA; Adlard J; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Arun BK; Ausems MGEM; Azzollini J; Barouk-Simonet E; Barwell J; Belotti M; Benitez J; Berger A; Borg A; Bradbury AR; Brunet J; Buys SS; Caldes T; Caligo MA; Campbell I; Caputo SM; Chiquette J; Claes KBM; Margriet Collée J; Couch FJ; Coupier I; Daly MB; Davidson R; Diez O; et al. 2019. J Natl Cancer Inst. 111(4): 350 - 364. IF:10,211.
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Ignatiadis M; Van den Eynden G; Roberto S; Fornili M; Bareche Y; Desmedt C; Rothé F; Maetens M; Venet D; Holgado E; McNally V; Kiermaier A; Savage HM; Wilson TR; Cortes J; Schneeweiss A; Willard-Gallo K; Biganzoli E; Sotiriou C. 2019. J Natl Cancer Inst. 111(1): 69 - 77. IF:10,211.
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G. 2019. Leukemia. 33(8): 1996 - 2005. IF:9,944.
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Martínez-Terroba E; Behrens C; Agorreta J; Monsó E; Millares L; Felip E; Rosell R; Ramirez JL; Remirez A; Torre W; Gil-Bazo I; Idoate MA; de-Torres JP; Pio R; Wistuba II; Pajares MJ; Montuenga LM. 2019. Thorax. 74(4): 371 - 379. IF: 9,640.
Genomic correlates of clinical outcome in advanced prostate cancer. Abida W; Cyrta J; Heller G; Prandi D; Armenia J; Coleman I; Cieslik M; Benelli M; Robinson D; Van Allen EM; Sboner A; Fedrizzi T; Mosquera JM; Robinson BD; De Sarkar N; Kunju LP; Tomlins S; Wu YM; Nava Rodrigues D; Loda M; Gopalan A; Reuter VE; Pritchard CC; Mateo J; et al. 2019. Proc Natl Acad Sci U S A. 116(23): 11428 - 11436. IF:9,580.
Repurposing dasatinib for diffuse large B cell lymphoma. Scuoppo C; Wang J; Persaud M; Mittan SK; Basso K; Pasqualucci L; Rabadan R; Inghirami G; Grandori C; Bosch F; Dalla-Favera R. 2019. Proc Natl Acad Sci U S A. 116(34): 16981 - 16986. IF:9,580.
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Blasco-Benito S; Moreno E; Seijo-Vila M; Tundidor I; Andradas C; Caffarel MM; Caro-Villalobos M; Urigüen L; Diez-Alarcia R; Moreno-Bueno G; Hernández L; Manso L; Homar-Ruano P; McCormick PJ; Bibic L; Bernadó-Morales C; Arribas J; Canals M; Casadó V; Canela EI; Guzmán M; Pérez-Gómez E; Sánchez C. 2019. Proc Natl Acad Sci U S A. 116(9): 3863 - 3872. IF:9,580.
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Atrafi F; Groen HJM; Byers LA; Garralda E; Lolkema MP; Sangha RS; Viteri S; Chae YK; Camidge DR; Gabrail NY; Hu B; Tian T; Nuthalapati S; Hoening E; He L; Komarnitsky P; Calles A. 2019. Clin Cancer Res. 25(2): 496 - 505. IF:8,911.
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J. 2019. Clin Cancer Res. 25(9): 2699 - 2707. IF:8,911.
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME. 2019. Clin Cancer Res. 25(9): 2717 - 2724. IF:8,911.
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E. 2019. Clin Cancer Res. 25(11): 3210 - 3219. IF:8,911.
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. Kang SA; Guan JS; Tan HJ; Chu T; Thike AA; Bernadó Morales C; Arribas J; Wong CY; Tan PH; Gudi M; Putti TC; Sohn J; Lim SH; Lee SC; Lim YP. 2019. Clin Cancer Res. 25(8): 2588 - 2600. IF:8,911.
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Ulaner GA; Saura C; Piha-Paul SA; Mayer IA; Quinn DI; Jhaveri K; Stone B; Shahin S; Mann G; Dujka M; Bryce R; Meric-Bernstam F; Solit DB; Hyman DM. 2019. Clin Cancer Res. 25(24): 7381 - 7387. IF:8,911.
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Bahleda R; Italiano A; Hierro C; Mita AC; Cervantes A; Chan N; Awad MM; Calvo E; Moreno V; Govindan R; Spira AI; Gonzalez MD; Zhong B; Santiago-Walker AE; Poggesi I; Parekh T; Xie H; Infante JR; Tabernero J. 2019. Clin Cancer Res. 25(16): 4888 - 4897. IF:8,911.
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S. 2019. Clin Cancer Res. 25(24): 7287 - 7293. IF:8,911.
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Jung KH; LoRusso PM; Burris HA; Gordon MS; Bang YJ; Hellmann MD; Cervantes A; Ochoa de Olza M; Marabelle A; Hodi FS; Ahn MJ; Emens LA; Barlesi F; Hamid O; Calvo E; McDermott DF; Soliman H; Rhee I; Lin R; Pourmohamad T; Suchomel J; Tsuhako A; Morrissey KM; Mahrus S; Morley R; Pirzkall A; Davis SL. 2019. Clin Cancer Res. 25(11): 3220 - 3228. IF:8,911.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly A; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Sridharan A; Gueorguieva I; Girvan A; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Will B; Verma A. 2019. Clin Cancer Res. 25(23): 6976 - 6985. IF:8,911.
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Pena L; Izquierdo MÁ; Huober J; Baselga J; Piccart M; De Braud FG; Apolone G; Verderio P; Daidone MG. 2019. Clin Cancer Res. 25(13): 3887 - 3895. IF:8,911.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Baird RD; van Rossum AG; Oliveira M; Beelen KJ; Gao M; Schrier M; Mandjes IA; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; Van Tinteren H; Callari M; Beddowes E; Pérez-Garcia J; Rosing H; Platte E; Nederlof PM; Schot M; de Vries Schultink AH; Bernards R; Saura C; Gallagher WM; Cortés J; Caldas C; Linn SC. 2019. Clin Cancer Res. 25(22): 6598 - 6605. IF:8,911.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekhar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H. 2019. Clin Cancer Res. 25(13): 3772 - 3775. IF:8,911.
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS. 2019. Clin Cancer Res. 25(2): 687 - 697. IF:8,911.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Hamid O; Molinero L; Bolen CR; Sosman JA; Muñoz-Couselo E; Kluger HM; McDermott DF; Powderly J; Sarkar I; Ballinger M; Fassò M; O’Hear C; Chen DS; Hegde PS; Hodi FS. 2019. Clin Cancer Res. 25(20): 6061 - 6072. IF:8,911.
Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Carrillo-Cruz E; García-Lozano JR; Márquez-Malaver FJ; Sánchez-Guijo FM; Montero Cuadrado I; Ferra I Coll C; Valcárcel D; López-Godino O; Cuesta M; Parody R; López-Corral L; Alcoceba M; Caballero-Velázquez T; Rodríguez-Gil A; Bejarano-García JA; Ramos TL; Pérez-Simón JA. 2019. Clin Cancer Res. 25(15): 4616 - 4623. IF:8,911.
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Solé A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monsó MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E. 2019. Cancer Res. 79(16): 4258 - 4270. IF:8,378.
TGF beta-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. Lambies G; Miceli M; Martínez-Guillamon C; Olivera-Salguero R; Peña R; Frías CP; Calderón I; Atanassov BS; Dent SYR; Arribas J; García de Herreros A; Díaz VM. 2019. Cancer Res. 79(1): 33 - 46. IF:8,378.
Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Seufferlein T; Hammel P; Delpero JR; Macarulla T; Pfeiffer P; Prager GW; Reni M; Falconi M; Philip PA; Van Cutsem E. 2019. Cancer Treat Rev. 77: 1 - 10. IF:8,332.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. Gavilá J; Oliveira M; Pascual T; Perez-Garcia J; Gonzàlez X; Canes J; Paré L; Calvo I; Ciruelos E; Muñoz M; Virizuela JA; Ruiz I; Andrés R; Perelló A; Martínez J; Morales S; Marín-Aguilera M; Martínez D; Quero JC; Llombart-Cussac A; Prat A. 2019. BMC MED. 17(1): 8 - 8. IF:8,285.
Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A. 2019. CELL DEATH DIFFER. IF:8,086.
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Rodríguez-Otero P; Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Bargay J; Bengoechea E; González Y; de Oteyza JP; Gironella M; Nuñez-Córdoba JM; Encinas C; Martín J; Cabrera C; Palomera L; de Arriba F; Cedena MT; Puig N; Oriol A; Paiva B; Bladé J; Lahuerta JJ; San Miguel JF. 2019. BLOOD CANCER J. 9(4): 36 - 36. IF:7,895.
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. De Mattos-Arruda L; Sammut SJ; Ross EM; Bashford-Rogers R; Greenstein E; Markus H; Morganella S; Teng Y; Maruvka Y; Pereira B; Rueda OM; Chin SF; Contente-Cuomo T; Mayor R; Arias A; Ali HR; Cope W; Tiezzi D; Dariush A; Dias Amarante T; Reshef D; Ciriaco N; Martinez-Saez E; Peg V; Ramon Y Cajal S; Cortes J; Vassiliou G; Getz G; Nik-Zainal S; Murtaza M; Friedman N; Markowetz F; Seoane J; Caldas C. 2019. Cell Rep. 27(9): 2690 - 2690. IF:7,815.
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Perez-Lopez R; Tunariu N; Padhani AR; Oyen WJG; Fanti S; Vargas HA; Omlin A; Morris MJ; de Bono J; Koh DM. 2019. Radiology. 292(2): 273 - 286. IF:7,608.
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Recasens-Zorzo C; Cardesa-Salzmann T; Petazzi P; Ros-Blanco L; Esteve-Arenys A; Clot G; Guerrero-Hernández M; Rodríguez V; Soldini D; Valera A; Moros A; Climent F; González-Barca E; Mercadal S; Arenillas L; Calvo X; Mate JL; Gutiérrez-García G; Casanova I; Mangues R; Sanjuan-Pla A; Bueno C; Menéndez P; Martínez A; Colomer D; Estrada-Tejedor R; Teixidó J; Campo E; López-Guillermo A; Borrell JI; Colomo L; Pérez-Galán P; Roué G. 2019. HAEMATOLOGICA. 104(4): 778 - 788. IF:7,570.
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R. 2019. J AUTOIMMUN. 103: 102285 - 102285. IF:7,543.
Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. Ramage JK; Valle JW; Nieveen van Dijkum EJM; Sundin A; Pascher A; Couvelard A; Kloeppel G; Bartsch D; Arnold R; Baudin E; Bodei L; Borbath I; Capdevila J; et al. 2019. Neuroendocrinology. 108(1): 45 - 53. IF:6,804.
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Capdevila J; Bodei L; Davies P; Gorbounova V; Jensen RT; Knigge U; J G; Krenning E; O’’Connor J; Peeters M; Rindi G; Salazar R; Vullierme MP; Pavel M. 2019. Neuroendocrinology. 108(1): 18 - 25. IF:6,804.
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. Baudin E; Hayes AR; Scoazec JY; Filosso PL; Lim E; Kaltsas G; Frilling A; Chen J; Kos-Kudla B; Gorbunova V; Wiedenmann B; Nieveen van Dijkum E; Cwikla JB; Falkerby J; Valle JW; Kulke MH; Caplin ME; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. 2019. Neuroendocrinology. 108(1): 7 - 17. IF:6,804.
Unmet Needs in Appendiceal Neuroendocrine Neoplasms.Toumpanakis C; Fazio N; Tiensuu Janson E; Hörsch D; Pascher A; Reed N; O Apos Toole D; Nieveen van Dijkum E; Partelli S; Rinke A; Kos-Kudla B; Costa F; Pape UF; Grozinsky-Glasberg S; Scoazec JY; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. 2019. Neuroendocrinology. 108(1): 37 - 44. IF:6,804.
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. Jensen RT; Bodei L; Capdevila J; Couvelard A; Falconi M; Glasberg S; Kloppel G; Lamberts S; Peeters M; Rindi G; Rinke A; Rothmund M; Sundin A; Welin S; Fazio N; The ENETS 2016 Munich Advisory Board Participants. 2019. Neuroendocrinology. 108(1): 26 - 36. IF:6,804.
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla, JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R; Arnold R; Bartsch D; Baudin E; Bodei L; Borbath I; Capdevila J et al. 2019. Neuroendocrinology. 108(1): 54 - 62. IF:6,804.
Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. de Herder WW; Capdevila J. 2019. Neuroendocrinology. 108(1): 5 - 6. IF:6,804.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >= 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R. 2019. Eur J Cancer. 107: 142 - 152. IF:6,680.
European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer. Rutgers E; Balmana J; Beishon M; Benn K; Evans DG; Mansel R; Pharoah P; Skinner VP; Stoppa-Lyonnet D; Travado L; Wyld L. 2019. Eur J Cancer. 106: 45 - 53. IF:6,680.
Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-a European consensus statement and expert recommendations. Singer CF; Balmana J; Burki N; Delaloge S; Filieri ME; Gerdes A-M; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG. 2019. Eur J Cancer. 106: 54 - 60. IF:6,680.
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J. 2019. Eur J Cancer. 112: 12 - 19. IF:6,680.
Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. de Rojas T; Clementel E; Giralt J; Cruz O; Boterberg T; Kortmann RD; Gaze MN; Mo reno L; Janssens GO; SIOP-Europe QUARTET Project and of the EORTC. 2019. Eur J Cancer. 114: 36 - 46. IF:6,680.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L. 2019. Eur J Cancer. 108: 120 - 128. IF:6,680.
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Schadendorf D; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Nathan P. 2019. Eur J Cancer. 121: 144 - 153. IF:6,680.
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D. 2019. Eur J Cancer. 119: 168 - 178. IF:6,680.
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Di Cosimo S; Triulzi T; Pizzamiglio S; De Cecco L; de Azambuja E; Fumagalli D; Putzai L; Harbeck N; Izquierdo M; Peña L; Daidone MG; Huober J; Gori S; Cinieri S; Torri V; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Tagliabue E. 2019. Eur J Cancer. 118: 1 - 9. IF:6,680.
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C. 2019. Eur J Cancer. 120: 1 - 9. IF:6,680.
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. Díaz-Rodríguez E; Pérez-Peña J; Ríos-Luci C; Arribas J; Ocaña A; Pandiella A. 2019. CANCER LETT. 453: 34 - 44. IF:6,508.
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P. 2019. Int J Radiat Oncol Biol Phys. 103(2): 344 - 352. IF:6,203.
BRCA2 and Other DDR Genes in Prostate Cancer. Nombela P; Lozano R; Aytes A; Mateo J; Olmos D; Castro E. 2019. Cancers (Basel). 11(3): 352. IF:6,162.
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Vitiello PP; De Falco V; Giunta EF; Ciardiello D; Cardone C; Vitale P; Zanaletti N; Borrelli C; Poliero L; Terminiello M; Arrichiello G; Caputo V; Famiglietti V; Mattera Iacono V; Marrone F; Di Liello A; Martini G; Napolitano S; Caraglia M; Lombardi A; Franco R; De Vita F; Morgillo F; Troiani T; Ciardiello F; Martinelli E. 2019. Cancers (Basel). 11(10): 1504. IF:6,162.
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT. 2019. Cancers (Basel). 11(8): 1068. IF:6,162.
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications. Reyes-Garau D; Ribeiro ML; Roué G. 2019. Cancers (Basel). 11(10): 1483. IF:6,162.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors. Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Baratam P; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P. 2019. Cancer. IF:6,102.
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Ribera JM; García O; Moreno MJ; Barba P; García-Cadenas I; Mercadal S; Montesinos P; Barrios M; González-Campos J; Martínez-Carballeira D; Gil C; Ribera J; Vives S; Novo A; Cervera M; Serrano J; Lavilla E; Abella E; Tormo M; Amigo ML; Artola MT; Genescà E; Bravo P; García-Belmonte D; García-Guiñón A; Hernández-Rivas JM; Feliu E; PETHEMA Group of the Spanish Society of Hematology. 2019. Cancer. 125(16): 2810 - 2817. IF:6,102.
Cancer Core Europe: A translational research infrastructure for a European mission on cancer. Eggermont AMM; Apolone G; Baumann M; Caldas C; Celis JE; de Lorenzo F; Ernberg I; Ringborg U; Rowell J; Tabernero J; Voest E; Calvo F. 2019. Mol Oncol. 13(3): 521 - 527. IF:5,962.
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Elez E; Chianese C; Sanz-García E; Martinelli E; Noguerido A; Mancuso FM; Caratù G; Matito J; Grasselli J; Cardone C; Esposito Abate R; Martini G; Santos C; Macarulla T; Argilés G; Capdevila J; Garcia A; Mulet N; Maiello E; Normanno N; Jones F; Tabernero J; Ciardello F; Salazar R; Vivancos A. 2019. Mol Oncol. 13(9): 1827 - 1835. IF:5,962.
New clinical trial designs in the era of precision medicine. Garralda E; Dienstmann R; Piris A; Braña I; Rodon J; Tabernero J. 2019. Mol Oncol. 13(3): 549 - 557. IF:5,962.
Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Selenica P; Raj N; Kumar R; Brown DN; Arqués O; Reidy D; Klimstra D; Snuderl M; Serrano J; Palmer HG; Weigelt B; Reis-Filho JS; Scaltriti M. 2019. Mol Oncol. 13(8): 1684 - 1692. IF:5,962.
Towards a Cancer Mission in Horizon Europe. Berns A; Ringborg U; Eggermont A; Baumann M; Calvo F; Eggert A; Espina C; Hanahan D; Lacombe D; de Lorenzo F; Oberst S; Philip T; Schüz J; Tabernero J; Celis JE. 2019. Mol Oncol. 13(11): 2301 - 2304. IF:5,962.
Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? Stradella A; Del Valle J; Rofes P; Feliubadaló L; Grau Garces È; Velasco À; González S; Vargas G; Izquierdo Á; Campos O; Tornero E; Navarro M; Balmaña-Gelpi J; Capellá G; Pineda M; Brunet J; Lázaro C. 2019. J MED GENET. 56(8): 521 - 525. IF:5,899.
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Bogliolo M; Pujol R; Aza-Carmona M; Muñoz-Subirana N; Rodriguez-Santiago B; Casado JA; Rio P; Bauser C; Reina-Castillón J; Lopez-Sanchez M; Gonzalez-Quereda L; Gallano P; Catalá A; Ruiz-Llobet A; Badell I; Diaz-Heredia C; Hladun R; Senent L; Argiles B; Bergua Burgues JM; Bañez F; Arrizabalaga B; López Almaraz R; Lopez M; Figuera Á; Molinés A; Pérez de Soto I; Hernando I; Muñoz JA; Del Rosario Marin M; Balmaña J; et al.2019. J MED GENET. IF:5,899.
Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer. Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S. 2019. J MED GENET. 56(2): 63 - 74. IF:5,899.
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Lopez-Bonet E; Buxó M; Cuyàs E; Pernas S; Dorca J; Álvarez I; Martínez S; Pérez-Garcia JM; Batista-López N; Rodríguez-Sánchez CA; Amillano K; Domínguez S; Luque M; Morilla I; Stradella A; Viñas G; Cortés J; Oliveras G; Meléndez C; Castillo L; Verdura S; Brunet J; Joven J; Garcia M; Saidani S; Martin-Castillo B; Menendez JA. 2019. J Clin Med. 8(12): 2180. IF:5,688.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A. 2019. Breast Cancer Res. 21(1): 108 - 108. IF:5,676.
Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Ravegnini G; Sammarini G; Serrano C; Nannini M; Pantaleo MA; Hrelia P; Angelini S. 2019. Ther Adv Med Oncol. 11: UNSP 1758835919831902. IF:5,670.
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Bellet M; Ahmad F; Villanueva R; Valdivia C; Palomino-Doza J; Ruiz A; Gonzàlez X; Adrover E; Azaro A; Valls-Margarit M; Parra JL; Aguilar J; Vidal M; Martín A; Gavilá J; Escrivá-de-Romaní S; Perelló A; Hernando C; Lahuerta A; Zamora P; Reyes V; Alcalde M; Masanas H; Céliz P; Ruíz I; Gil M; Seguí MÀ; de la Peña L. 2019. Ther Adv Med Oncol. 11: 1758835919833867. IF:5,670.
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E. 2019. J Exp Clin Cancer Res. 38(1): 41 - 41. IF:5,646.
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T. 2019. J Exp Clin Cancer Res. 38(1): 492 - 492. IF:5,646.
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Cuyàs E; Fernández-Arroyo S; Buxó M; Pernas S; Dorca J; Álvarez I; Martínez S; Pérez-Garcia JM; Batista-López N; Rodríguez-Sánchez CA; Amillano K; Domínguez S; Luque M; Morilla I; Stradella A; Viñas G; Cortés J; Verdura S; Brunet J; López-Bonet E; Garcia M; Saidani S; Joven J; Martin-Castillo B; Menendez JA. 2019. Aging (Albany NY). 11(9): 2874 - 2888. IF:5,515.
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Gorbunova, V; Beck JT; Hofheinz R.-D; Garcia-Alfonso P; Nechaeva M; Cubillo Gracian A; Mangel L; Elez Fernandez E; Deming DA; Ramanathan RK; Torres AH; Sullivan D; Luo Y; Berlin JD. 2019. Br J Cancer. 120(2): 183 - 189. IF:5,416.
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. Elez E; Pericay C; Valladares-Ayerbes M; Bando I; Safont MJ; Gallego J; Grávalos C; Arrivi A; Carrato A; Conde V; Ortiz MJ; López C; Alonso B; Ruiz de Mena I; Díaz-Rubio E; Tabernero J; Aranda E. 2019. Br J Cancer. 121(5): 378 - 383. IF:5,416.
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. Auclin E; André T; Taieb J; Banzi M; Van Laethem JL; Tabernero J; Hickish T; de Gramont A; Vernerey D. 2019. Br J Cancer. 121(4): 312 - 317. IF:5,416.
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA. 2019. Br J Cancer. 120(6): 612 - 620. IF:5,416.
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P. 2019. Br J Cancer. 121(7): 537 - 544. IF:5,416.
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Qian F; Rookus MA; Leslie G; Risch HA; Greene MH; Aalfs CM; Adank MA; Adlard J; Agnarsson BA; Ahmed M; Aittomäki K; Andrulis IL; Arnold N; Arun BK; Ausems MGEM; Azzollini J; Barrowdale D; Barwell J; Benitez J; Bialkowska K; Bonadona V; Borde J; Borg A; Bradbury AR; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Carter J; Chiquette J; Chung WK; Claes KBM; Collée JM; Collonge-Rame MA; Couch FJ; Daly MB; Delnatte C; Diez O; et al. 2019. Br J Cancer. 121(2): 180 - 192. IF:5,416.
Clinical Management of Adverse Events Associated with Lorlatinib. Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT. 2019. Oncologist. 24(8): 1103 - 1110. IF:5,252.
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J. 2019. Oncologist. 24(5): 680 - 687. IF:5,252.
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Putora PM; Glatzer M; De Ruysscher D; Faivre-Finn C; Belderbos J; Besse B; Blackhall F; Califano R; Cappuzzo F; de Marinis F; Dziadiuszko R; Felip E; Früh M; Garrido P; Le Pechoux C; McDonald F; Nestle U; Novello S; Brien MO; Paz Ares L; Peeters S; Pöttgen S; Ramella S; Reck M; Troost EGC; Van Houtte P; Westeel V; Widder J; Mornex F; Slotman BJ. 2019. Radiother Oncol. 135: 74 - 77. IF:5,252.
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials. Pérez-Garcia J; Cortés J; Metzger Filho O. 2019. Oncologist. 24(8): 1041 - 1047. IF:5,252
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E. 2019. Oncologist. 24(7): 893 - 900. IF:5,252
Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Capdevila J; Hernando J; Perez-Hoyos S; Roman-Gonzalez A; Grande E. 2019. Oncologist. 24(12): 1315 - 1320. IF:5,252
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Colomer R; Saura C; Sánchez-Rovira P; Pascual T; Rubio IT; Burgués O; Marcos L; Rodríguez CA; Martín M; Lluch A. 2019. Oncologist. 24(5): 603 - 611. IF:5,252
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R; EVERLAR study investigators. 2019. Oncologist. 24(1): 38 - 46. IF:5,252.
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Putora PM; Glatzer M; Belderbos J; Besse B; Blackhall F; Califano R; Cappuzzo F; de Marinis F; Dziadziuszko R; Felip E; et al. 2019. Radiother Oncol. 133: 163 - 166. IF:5,252.
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA. 2019. Oncologist. 24(8): 1095 - 1102. IF:5,252.
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A. 2019. Oncologist. 24(10): 1375 - 1383. IF:5,252.
Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Martin-Broto J; Hindi N; Cruz J; Martinez-Trufero J; Valverde C; De Sande LM; Sala A; Bellido L; De Juan A; Rubió-Casadevall J; Diaz-Beveridge R; Cubedo R; Tendero O; Salinas D; Gracia I; Ramos R; Baguè S; Gutierrez A; Duran-Moreno J; Lopez-Pousa A. 2019. Oncologist. 24(6): 338 - 346. IF:5,252.
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Seibold P; Webb A; Aguado-Barrera ME; Azria D; Bourgier C; Brengues M; Briers E; Bultijnck R; Calvo-Crespo P; Carballo A; Choudhury A; Cicchetti A; Claßen J; Delmastro E; Dunning AM; Elliott RM; Farcy-Jacquet MP; Gabriele P; Garibaldi E; Gómez-Caamaño A; Gutiérrez-Enríquez S; et al. 2019. Radiother Oncol. 138: 59 - 67. IF:5,252.
Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Biau J; Lapeyre M; Troussier I; Budach W; Giralt J; Grau C; Kazmierska J; Langendijk JA; Ozsahin M; O’Sullivan B; Bourhis J; Grégoire V. 2019. Radiother Oncol. 134: 1 - 9. IF:5,252.
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). 2019. Br J Haematol. 184(5): 797 - 807. IF:5,206.
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A. 2019. Br J Haematol. IF:5,206.
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E; Spanish Group of MDS (GESMD). 2019. Br J Haematol. IF:5,206.
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. Ribera J; Granada I; Morgades M; Vives S; Genescà E; González C; Nomdedeu J; Escoda L; Montesinos P; Mercadal S; Coll R; González-Campos J; Abella E; Barba P; Bermúdez A; Gil C; Tormo M; Pedreño M; Martínez-Carballeira D; Hernández-Rivas JM; Orfao A; Martínez-López J; Esteve J; Bravo P; Garcia-Guiñon A; Debén G; Moraleda JM; Queizán JA; Ortín X; Moreno MJ; Feliu E; Solé F; Ribera JM; PETHEMA Group, Spanish Society of Haematology. 2019. Br J Haematol. 186(2): 263 - 268. IF:5,206.
Editorial overview: Peptides in cancer. Whitfield J; Soucek L. 2019. CURR OPIN PHARMACOL. 47: iii-v. IF:5,203.
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. Auclin E; Taieb J; Lepage C; Aparicio T; Faroux R; Mini E; Folprecht G; Salazar R; Benetkiewicz M; Banzi M; Louvet C; Van Laethem JL; Tabernero J; Hickish T; de Gramont A; André T; Vernerey D. 2019. Cancer Epidemiol Biomarkers Prev. 28(7): 1153 - 1161. IF:5,057.
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E. 2019. Crit Rev Oncol Hematol. 138: 190 - 206. IF:5,012.
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Cristofanilli M; Pierga JY; Reuben J; Rademaker A; Davis AA; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Giuliano M; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; et al. 2019. Crit Rev Oncol Hematol. 134: 39 - 45. IF:5,012.
Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R. 2019. INT J CANCER. 144(8): 1983 - 1995. IF:4,982.
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M. 2019. INT J CANCER. 145(3): 748 - 762. IF:4,982.
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J; Catalan Hereditary Cancer Group. 2019. INT J CANCER. 145(10): 2682 - 2691. IF:4,982.
Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; Investigators K; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ. 2019. INT J CANCER. 145(2): 401 - 414. IF:4,982.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domenech M; Rodríguez-Vida A; Carles J; Suárez C; González Del Alba A; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B. 2019. INT J CANCER. 145(7): 1970 - 1981. IF:4,982.
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Nadal E; Massuti B; Dómine M; García-Campelo R; Cobo M; Felip E. 2019. Cancer Immunol Immunother. 68(3): 341 - 352. IF:4,900.
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs. Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T. 2019. Mol Cancer Ther. 18(4): 771 - 779. IF:4,856.
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M. 2019. Mol Cancer Ther. 18(9): 1533 - 1543. IF:4,856.
Proteomics Analysis of Extracellular Matrix Remodeling During Zebrafish Heart Regeneration. Garcia-Puig A; Mosquera JL; Jiménez-Delgado S; García-Pastor C; Jorba I; Navajas D; Canals F; Raya A. 2019. MOL CELL PROTEOMICS. 18(9): 1745 - 1755. IF:4,828.
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Martinez-Marti A; Navarro A; Felip E. 2019. Transl Lung Cancer Res. 8(3): 235 - 246. IF:4,806.
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Yao JC; Garg A; Chen D; Capdevila J; Engstrom P; Pommier R; Van Cutsem E; Singh S; Fazio N; He W; Riester M; Patel P; Voi M; Morrissey M; Pavel ME; Kulke MH. 2019. Endocr Relat Cancer. 26(4): 391 - 403. IF:4,774.
Determinants for Neoantigen Identification. Garcia-Garijo A; Fajardo CA; Gros A. 2019. FRONT IMMUNOL. 10: 1392 - 1392. IF:4,716.
Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. Ortí G; Iacoboni G; Barba P; Gimeno R; Roldán E; Fox L; Salamero O; Bosch F; Valcárcel D. 2019. Bone Marrow Transplant. 54(5): 772 - 774. IF:4,674.
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. Ortí G; García-Cadenas I; López L; Pérez A; Jimenez MJ; Sánchez-Ortega I; Alonso L; Sisinni L; Fox L; Villacampa G; Badell I; de Heredia CD; Parody R; Ferrà C; Solano C; Caballero D; Martino R; Querol S; Valcárcel D. 2019. Bone Marrow Transplant. 54(7): 1133 - 1137. IF:4,674.
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA; Grupo Español de Trasplante Hematopoyético (GETH). 2019. Bone Marrow Transplant. IF:4,674.
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Morgensztern D; Karaseva N; Felip E; Delgado I; Burdaeva O; Dómine M; Lara P; Paik PK; Lassen U; Orlov S; Trigo J; Shomova M; Baker-Neblett K; Vasquez J; Wang X; Yan L; Mitrica I; DeYoung MP; Garrido P. 2019. Lung Cancer. 136: 74 - 79. IF:4,599.
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P. 2019. Lung Cancer. 134: 72 - 78. IF:4,599.
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G. 2019. Lung Cancer. 135: 188 - 195. IF:4,599.
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D. 2019. Lung Cancer. 133: 83 - 87. IF:4,599.
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J. 2019. BJU INT. 123(3): 456 - 464. IF:4,524.
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Selkirk CH; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; Eeles RA; Aaronson NK; Eeles R; Bancroft E; Page E; Kote-Jarai Z; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Falconer A; Foster C; Gronberg H; Hamdy FC; Johannsson OT; Khoo V; Eccles D; Lilja H; Evans G; Eyfjord J; Lubinski J; Maehle L; Mikropoulos C; Millner A; Mitra A; Offman J; Moynihan C; Rennert G; Suri M; Dias A; Taylor N; D’Mello L; Pope J; James P; Mitchell G; Shanley S; Richardson K; McKinley J; Petelin L; Murphy M; Mascarenhas L; Murphy D; Lam J; Taylor L; Miller C; Stapleton A; Chong M; Suthers G; Poplawski N; Tucker K; Andrews L; Duffy J; Millard R; Ward R; Williams R; Stricker P; Kirk J; Bowman M; Patel M; Harris M; O’Connell S; Hunt C; Smyth C; Frydenberg M; Lindeman G; Shackleton K; Morton C; Susman R; McGaughran J; Boon M; Pachter N; Townshend S; Schofield L; Nicholls C; Spigelman A; Gleeson M; Amor D; Burke J; Patterson B; Swindle P; Scott R; Foulkes W; Boshari T; Aprikian A; Jensen T; Bojeson A; Osther P; Skytte A-B; Cruger D; Tondering MK; Gerdes A-M; Schmutzler R; Rhiem K; Wihler P; Kast K; Griebsch C; Johannsson O; Stefansdottir V; Murthy V; Sarin R; Awatagiri K; Ghonge S; Kowtal P; Mulgund G; Gallagher D; Bambury R; Farrell M; Gallagher F; Kiernan I; Friedman E; Chen-Shtoyerman R; Basevitch A; Leibovici D; Melzer E; Ben-Yehoshua SJ; Nicolai N; Radice P; Valdagni R; Magnani T; Gay S; Teo SH; Tan HM; Yoon S-Y; Thong MK; Vasen H; Ringleberg J; van Asperen C; Kiemeney B; van Zelst-Stams W; Ausems MGEM; van der Luijt RB; van Os T; Ruijs MWG; Adank MA; Oldenburg RA; Helderman-van den Enden APTJM; Caanen BAH; Oosterwijk JC; Moller P; Brennhovd B; Medvik H; Hanslien E; Grindedal EM; Cybulski C; Wokolorczyk D; Teixeira M; Maia S; Peixoto A; Henrique R; Oliveira J; Goncalves, N; Araujo L; Seixas M; Souto JP; Nogueira P; Copakova L; Zgajnar J; Krajc M; Vrecar A; Capella G; Ramon y Cajal T; Fisas D; Mora J; Esquena S; Balmaña J; et al. 2019. BJU INT. 123(2): 284 - 292. IF:4,524.
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Solé A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E. 2019. MOL CANCER RES. 17(10): 2063 - 2076. IF:4,484.
Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. Cline MS; Babbi G; Bonache S; Cao Y; Casadio R; de la Cruz X; Díez O; Gutiérrez-Enríquez S; Katsonis P; Lai C; Lichtarge O; Martelli PL; Mishne G; Moles-Fernández A; Montalban G; Mooney SD; O’Conner R; Ootes L; Özkan S; Padilla N; Pagel KA; Pejaver V; Radivojac P; Riera C; Savojardo C; Shen Y; Sun Y; Topper S; Parsons MT; Spurdle AB; Goldgar DE; ENIGMA Consortium. 2019. Hum Mutat. 40(9): 1546 - 1556. IF:4,453.
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Friebel TM; Andrulis IL; Balmaña J; Blanco AM; Couch FJ; Daly MB; Domchek SM; Easton DF; Foulkes WD; Ganz PA; Garber J; Glendon G; Greene MH; Hulick PJ; Isaacs C; Jankowitz RC; Karlan BY; Kirk J; Kwong A; Lee A; Lesueur F; Lu KH; Nathanson KL; Neuhausen SL; Offit K; Palmero EI; Sharma P; Tischkowitz M; Toland AE; Tung N; van Rensburg EJ; Vega A; Weitzel JN; Collaborators GS; Hoskins KF; Maga T; Parsons MT; McGuffog L; Antoniou AC; Chenevix-Trench G; Huo D; Olopade OI; Rebbeck TR. 2019. Hum Mutat. 40(10): 1781 - 1796. IF:4,453
BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge. Padilla N; Moles-Fernández A; Riera C; Montalban G; Özkan S; Ootes L; Bonache S; Díez O; Gutiérrez-Enríquez S; de la Cruz X. 2019. Hum Mutat. 40(9): 1593 - 1611. IF:4,453.
Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes. Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S. 2019. Hum Mutat. 40(12): 2296 - 2317. IF:4,453.
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Parsons MT; Tudini E; Li H; Hahnen E; Wappenschmidt B; Feliubadaló L; Aalfs CM; Agata S; Aittomäki K; Alducci E; Alonso-Cerezo MC; Arnold N; Auber B; Austin R; Azzollini J; Balmaña J; Barbieri E; Bartram CR; Blanco A; Blümcke B; Bonache S; Bonanni B; Borg Å; Bortesi B; Brunet J; Bruzzone C; Bucksch K; Cagnoli G; Caldés T; Caliebe A; Caligo MA; Calvello M; Capone GL; Caputo SM; Carnevali I; Carrasco E; Caux-Moncoutier V; Cavalli P; Cini G; Clarke EM; Concolino P; Cops EJ; Cortesi L; Couch FJ; Darder E; de la Hoya M; Dean M; Debatin I; Del Valle J; Delnatte C; Derive N; Diez O; Ditsch N; Domchek SM; Dutrannoy V; Eccles DM; Ehrencrona H; Enders U; Evans DG; Faust U; Felbor U; Feroce I; Fine M; Galvao HCR; Gambino G; Gehrig A; Gensini F; Gerdes AM; Germani A; Giesecke J; Gismondi V; Gómez C; Gómez Garcia EB; González S; Grau E; Grill S; Gross E; Guerrieri-Gonzaga A; Guillaud-Bataille M; Gutiérrez-Enríquez S; Haaf T; Hackmann K; Hansen TVO; Harris M; Hauke J; Heinrich T; Hellebrand H; Herold KN; Honisch E; Horvath J; Houdayer C; Hübbel V; Iglesias S; Izquierdo A; James PA; Janssen LAM; Jeschke U; Kaulfuß S; Keupp K; Kiechle M; Kölbl A; Krieger S; Kruse TA; Kvist A; Lalloo F; Larsen M; Lattimore VL; Lautrup C; Ledig S; Leinert E; Lewis AL; Lim J; Loeffler M; López-Fernández A; Lucci-Cordisco E; Maass N; Manoukian S; Marabelli M; Matricardi L; Meindl A; Michelli RD; Moghadasi S; Moles-Fernández A; Montagna M; Montalban G; Monteiro AN; Montes E; Mori L; Moserle L; Müller CR; Mundhenke C; Naldi N; Nathanson KL; Navarro M; Nevanlinna H; Nichols CB; Niederacher D; Nielsen HR; Ong KR; Pachter N; Palmero EI; Papi L; Pedersen IS; Peissel B; Pérez-Segura P; Pfeifer K; Pineda M; Pohl-Rescigno E; Poplawski NK; Porfirio B; Quante AS; Ramser J; Reis RM; Revillion F; Rhiem K; Riboli B; Ritter J; Rivera D; Rofes P; Rump A; Salinas M; Sánchez de Abajo AM; Schmidt G; Schoenwiese U; Seggewiß J; Solanes A; Steinemann D; Stiller M; Stoppa-Lyonnet D; Sullivan KJ; Susman R; Sutter C; Tavtigian SV; Teo SH; Teulé A; Thomassen M; Tibiletti MG; Tognazzo S; Toland AE; Tornero E; Törngren T; Torres-Esquius S; et al. 2019. Hum Mutat. 40: 1557 - 1578. IF:4,453.
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dientsmann R; Oaknin A. 2019. GYNECOL ONCOL. 152(2): 270 - 277. IF:4,393.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Liu JF; Gordon M; Veneris J; Braiteh F; Balmanoukian A; Eder JP; Oaknin A; Hamilton E; Wang Y; Sarkar I; Molinero L; Fassò M; O’Hear C; Lin YG; Emens LA. 2019. GYNECOL ONCOL. 154(2): 314 - 322. IF:4,393.
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Felip I; Moiola CP; Megino-Luque C; Lopez-Gil C; Cabrera S; Solé-Sánchez S; Muñoz-Guardiola P; Megias-Roda E; Pérez-Montoyo H; Alfon J; Yeste-Velasco M; Santacana M; Dolcet X; Reques A; Oaknin A; Rodríguez-Freixinos V; Lizcano JM; Domènech C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N. 2019. GYNECOL ONCOL. 153(2): 425 - 435. IF:4,393.
Sweet and Sour Ehrlichia: Glycoproteomics and Phosphoproteomics Reveal New Players in Ehrlichia ruminantium Physiology and Pathogenesis. Marcelino I; Colomé-Calls N; Holzmuller P; Lisacek F; Reynaud Y; Canals F; Vachiéry N. 2019. FRONT MICROBIOL. 10: 450 - 450. IF:4,259.
Clinical Implications of Extracellular HMGA1 in Breast Cancer. Méndez O; Pérez J; Soberino J; Racca F; Cortés J; Villanueva J. 2019. INT J MOL SCI. 20(23): 5950. IF:4,183.
Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. Ramos J; Vega JF; Cruz V; Sanchez-Sanchez E; Cortes J; Martinez-Salazar J. 2019. INT J MOL SCI. 20(5): 1076. IF:4,183.
The rs17084733 variant in the KIT 3’ UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S. 2019. Epigenetics. 14(6): 545 - 557. IF:4,173.
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Pascual T; Martin M; Fernández-Martínez A; Paré L; Alba E; Rodríguez-Lescure Á; Perrone G; Cortés J; Morales S; Lluch A; Urruticoechea A; González-Farré B; Galván P; Jares P; Rodriguez A; Chic N; Righi D; Cejalvo JM; Tonini G; Adamo B; Vidal M; Villagrasa P; Muñoz M; Prat A. 2019. Front Oncol. 9: 303 - 303. IF:4,137.
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Levy B; Paz-Ares L; Bennouna J; Felip E; Abreu DR; Isla D; Barlesi F; Molinier O; Madelaine J; Audigier-Valette C; Kim SW; Kim HR; Ozguroglu M; Erman M; Badin FB; Mekhail TM; Scheff R; Chisamore MJ; Sadrolhefazi B; Riess JW. 2019. CLIN LUNG CANCER. 20(3): 407 - 412. IF:4,117.
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N. 2019. J TRANSL MED. 17(1): 429 - 429. IF:4,098.
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Martin-Liberal J; Pérez E; García Del Muro X. 2019. Expert Opin Investig Drugs. 28(1): 39 - 50. IF:4,031.
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials. Matos I; Noguerido A; Ros J; Mulet N; Argilés G; Elez É; Tabernero J. 2019. Expert Opin Investig Drugs. 28(5): 463 - 471. IF:4,031.
A proteomic analysis of the statocyst endolymph in common cuttlefish (Sepia officinalis): an assessment of acoustic trauma after exposure to sound. Solé M; Monge M; André M; Quero C. 2019. Sci Rep. 9(1): 9340 - 9340. IF:4,011.
Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Borrero-Palacios A; Cebrián A; Gómez Del Pulgar MT; García-Carbonero R; García P; Aranda E; Elez E; López-López R; Cervantes A; Valladares M; Nadal C; Viéitez JM; Guillén-Ponce C; Rodríguez J; Hernández I; García JL; Vega-Bravo R; Puime-Otin A; Martínez-Useros J; Del Puerto-Nevado L; Rincón R; Rodríguez-Remírez M; Rojo F; García-Foncillas J. 2019. Sci Rep. 9: 2589 - 2589. IF:4,011.
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E. 2019. Sci Rep. 9: 8976 - 8976. IF:4,011.
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V. 2019. Sci Rep. 9(1): 16680 - 16680. IF:4,011.
HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503. Gorbatenko A; Søkilde R; Sorensen EE; Newie I; Persson H; Morancho B; Arribas J; Litman T; Rovira C; Pedersen SF. 2019. Sci Rep. 9: 3352 - 3352. IF:4,011.
Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms. Cabezas M; García-Quevedo L; Alonso C; Manubens M; Álvarez Y; Barquinero JF; Ramón Y Cajal S; Ortega M; Blanco A; Caballín MR; Armengol G. 2019. Sci Rep. 9: 150 - 150. IF:4,011.
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Serna G; Ruiz-Pace F; Cecchi F; Fasani R; Jimenez J; Thyparambil S; Landolfi S; Elez E; Vivancos A; Hembrough T; Tabernero J; Dienstmann R; Nuciforo P. 2019. Sci Rep. 9: 13568 - 13568. IF:4,011.
Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J. 2019. CURR ONCOL REP. 21(5): 42 - 42. IF:3,949.
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J. 2019. Health Technol Assess. 23(64): 1 - 88. IF:3,819.
Nanoparticles as theranostic vehicles in prostate cancer. Morales-Barrera R; Suárez C; Mateo J; González M; Carles J. 2019. Ann Transl Med. 7(1): S29. IF:3,689.
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Font A; Luque R; Villa JC; Domenech M; Vázquez S; Gallardo E; Virizuela JA; Beato C; Morales-Barrera R; Gelabert A; Maciá S; Puente J; Rubio G; Maldonado X; Perez-Valderrama B; Pinto A; Fernández Calvo O; Grande E; Garde-Noguera J; Fernández-Parra E; Arranz JÁ. 2019. Target Oncol. 14(1): 15 - 32. IF:3,683.
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL. 2019. Biol Blood Marrow Transplant. 25(5): 1022 - 1030. IF:3,599.
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A; Grupo Español de Trasplante Hematopoyético (GETH). 2019. Biol Blood Marrow Transplant. 25(9): 1825 - 1831. IF:3,599.
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Grande E; Díaz Á; López C; Munarriz J; Reina JJ; Vera R; Bernárdez B; Aller J; Capdevila J; Garcia-Carbonero R; Jimenez Fonseca P; Trapero-Bertran M. 2019. Ther Adv Endocrinol Metab. 10: UNSP 2042018819828217. IF:3,543.
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G. 2019. Front Genet. 10: 986 - 986. IF:3,517.
How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2). Montagna G; Anderson D; Bochenek-Cibor J; Bozovic-Spasojevic I; Campos C; Cavallero S; Durutovic I; Gomez Cuadra MO; Irfan T; Joly L; Kassem L; Kolben TM; Machacek M; Mir Khan B; Nagvekar M; Pellegrino B; Pogoda K; Câmara GR; Ferreira PS; Seferi M; Talibova N; Van den Rul N; Vettus E; Rocco N. 2019. Breast. 43: 18 - 21. IF:3,494.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE. 2019. Breast Cancer Res Treat. 178(1): 121 - 133. IF:3,471.
Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G > T. Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O. 2019. Breast Cancer Res Treat. 174(2): 543 - 550. IF:3,471.
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group). 2019. Cancer Med. 8(16): 6955 - 6966. IF:3,357.
Window of Opportunity trials for biomarker discovery in breast cancer. Arnedos M; Roulleaux Degage M; Perez-Garcia J; Cortes J. 2019. CURR OPIN ONCOL. 31(6): 486 - 492. IF:3,261.
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Cazzaniga ME; Munzone E; Bocci G; Afonso N; Gomez P; Langkjer S; Petru E; Pivot X; Sánchez Rovira P; Wysocki P; Torri V. 2019. ADV THER. 36(2): 381 - 406. IF:3,260.
Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. Pérez-Gracia JL; Castellano D; Climent MÁ; Mellado B; Suárez C. 2019. MED ONCOL. 36(3): 29 - 29. IF:3,252.
The safety of eribulin for the treatment of metastatic breast cancer. Perez-Garcia JM; Cortes J. 2019. EXPERT OPIN DRUG SAF. 18(5): 347 - 355. IF:3,220.
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Lenz HJ; Argiles G; Yoshino T; Lonardi S; Falcone A; Limón ML; Sobrero A; Hastedt C; Peil B; Voss F; Griebsch I; Van Cutsem E. 2019. Clin Colorectal Cancer. 18(4): 269 - 269. IF:3,176.
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA. 2019. J GERIATR ONCOL. 10(3): 427 - 435. IF:3,164.
Management and supportive treatment of frail patients with metastatic pancreatic cancer. Macarulla T; Carrato A; Díaz R; García A; Laquente B; Sastre J; Álvarez R; Muñoz A; Hidalgo M. 2019. J GERIATR ONCOL. 10(3): 398 - 404. IF:3,164.
Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial. Buckland G; Travier N; Arribas L; Del Barco S; Pernas S; Zamora E; Bellet M; Cirauqui B; Margelí M; Muñoz M; Tusquets I; Arcusa A; Javierre C; Moreno F; Valverde Y; Jansen E; Chajès V; Castro C; Agudo A. 2019. J HUM NUTR DIET. 32(4): 468 - 479. IF:3,088.
Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study. Aguilar-Company J; Martín MT; Goterris-Bonet L; Martinez-Marti A; Sampol J; Roldán E; Almirante B; Ruiz-Camps I. 2019. Mycoses. 62(9): 765 - 772. IF:3,065.
Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Johnson K; Chang-Claude J; Critchley AM; Kyriacou C; Lavers S; Rattay T; Seibold P; Webb A; West C; Symonds RP; Talbot CJ; REQUITE Consortium. 2019. Clin Oncol (R Coll Radiol). 31(1): 9 - 16. IF:3,047.
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. Cubillo A; Álvarez-Gallego R; Muñoz M; Pond G; Perea S; Sánchez G; Martin M; Rodríguez-Pascual J; Garralda E; Vega E; de Vicente E; Quijano Y; Muñoz C; Ugidos L; Toledo RA; Hidalgo M. 2019. Am J Clin Oncol. 42(1): 56 - 59. IF:3,015.
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Kirschbrown WP; Wang B; Nijem I; Ohtsu A; Hoff PM; Shah MA; Shen L; Kang YK; Alsina M; Girish S; Garg A. 2019. Cancer Chemother Pharmacol. 84(3): 539 - 550. IF:3,008.
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-beta inhibitor galunisertib in patients with pancreatic cancer. Gueorguieva I; Tabernero J; Melisi D; Macarulla T; Merz V; Waterhouse TH; Miles C; Lahn MM; Cleverly A; Benhadji KA. 2019. Cancer Chemother Pharmacol. 84(5): 1003 - 1015. IF:3,008.
TGF beta receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J. 2019. Cancer Chemother Pharmacol. 83(5): 975 - 991. IF:3,008.
Off-pump technique and replacement therapy for coronary artery bypass surgery in a patient with hemophilia B. Fernández-Caballero M; Martinez MF; Oristrell G; Palmer N; Santamaría A. 2019. J Thromb Thrombolysis. 48(2): 299 - 302. IF:2,941.
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology. 2019. Genes Chromosomes Cancer. 58(11): 815 - 819. IF:2,940.
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas. Pilco-Janeta D; De la Cruz Puebla M; Soriano J; Osorio M; Caballero I; Pérez AC; Savon L; Cremades N; Blanco R; Carr A. 2019. BMC Cancer. 19(1): 556 - 556. IF:2,933.
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. Heidenreich A; Gillessen S; Heinrich D; Keizman D; O’Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F. 2019. BMC Cancer. 19: 12 - 12. IF:2,933.
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME; CLARINET Study Group. 2019. BMC Cancer. 19(1): 66 - 66. IF:2,933.
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis A novel variant of BRAF inhibitor associated panniculitis with histiocytoid infiltrate of immature neutrophils. Richarz NA; Puig L; Pérez N; Cuadra-Urteaga J; Elez E; Fernández-Figueras MT. 2019. CANCER BIOL THER. 20(3): 237 - 239. IF:2,879.
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. Caballero JC; Sánchez Barba M; Hernández Sánchez JM; Such E; Janusz K; Sanz G; Cabrero M; Chillón C; Cervera J; Hurtado AM; Jerez A; Calderón Cabrera C; Valcárcel D; Lumbreras E; Abáigar M; López Cadenas F; Hernández Rivas JM; Del Cañizo MC; Díez Campelo M. 2019. ANN HEMATOL. 98(9): 2151 - 2162. IF:2,850.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). 2019. ANN HEMATOL. 98(2): 321 - 330. IF:2,850.
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A. 2019. Clin Breast Cancer. 19(2): 105 - 112. IF:2,762
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups. 2019. Leuk Lymphoma. 60(4): 1030 - 1035. IF:2,674.
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D. 2019. Leuk Lymphoma. 60(6): 1522 - 1527. IF:2,674.
Real life outcomes of patients aged >= 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Salamero O; Martínez-Cuadrón D; Sobas M; Benavente C; Vives S; De la Serna J; Pérez-Encinas M; Escoda L; Gil C; Brunet S; Ramos F; Esteve J; Amigo M; Krsnik I; Manso F; Arias J; González-Campos J; Serrano J; Oleksiuk J; Barrios M; García-Boyero R; Novo A; Sanz MA; Montesinos P; PETHEMA and PALG Groups. 2019. Leuk Lymphoma. 60(11): 2720 - 2732. IF:2,674.
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D. 2019. Invest New Drugs. 37(2): 271 - 281. IF:2,663.
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP. 2019. Invest New Drugs. 37(4): 674 - 683. IF:2,663.
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Sankhala K; Takimoto CH; Mita AC; Xiong H; Rodón J; Mehrvarz Sarshekeh A; Burns K; Iizuka K; Kopetz S. 2019. Invest New Drugs. 37(1): 76 - 86. IF:2,663.
Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. Selva-O’Callaghan A; Ros J; Gil-Vila A; Vila-Pijoan G; Trallero-Araguás E; Pinal-Fernandez I. 2019. Neuromuscul Disord. 29(11): 819 - 825. IF:2,612.
Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study. Maciel RMB; Camacho CP; Assumpção LVM; Bufalo NE; Carvalho AL; de Carvalho GA; Castroneves LA; de Castro FM; Ceolin L; Cerutti JM; Corbo R; Ferraz TMBL; Ferreira CV; França MIC; Galvão HCR; Germano-Neto F; Graf H; Jorge AAL; Kunii IS; Lauria MW; Leal VLG; Lindsey SC; Lourenço DM; Maciel LMZ; Magalhães PKR; Martins JRM; Martins-Costa MC; Mazeto GMFS; Impellizzeri AI; Nogueira CR; Palmero EI; Pessoa CHCN; Prada B; Siqueira DR; Sousa MSA; Toledo RA; Valente FOF; Vaisman F; Ward LS; Weber SS; Weiss RV; Yang JH; Dias-da-Silva MR; Hoff AO; Toledo SPA; Maia AL. 2019. Endocr Connect. 8(3): 289 - 298. IF:2,474.
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Saad F; Gillessen S; Heinrich D; Keizman D; O’Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A. 2019. Clin Genitourin Cancer. 17(5): 348 - 348. IF:2,450.
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. Vuong HV; Ho ATN; TranTTK; Capdevila J; Benekli M; Nakazawa T; Katoh R; Kondo T. 2019. Head Neck. 41(8): 2823 - 2829. IF:2,442.
Are there enough radiation oncologists to lead the new Spanish radiotherapy? Rodríguez A; Arenas M; Lara PC; López-Torrecilla J; Algara M; Conde A; Pérez-Montero H; Muñoz JL; Peleteiro P; Pérez-Calatayud MJ; Contreras J; Ferrer C; Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group. 2019. Clin Transl Oncol. 21(12): 1663 - 1672. IF:2,441.
Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994-2013). Roca-Barceló A; Viñas G; Pla H; Carbó A; Comas R; Izquierdo Á; Pinheiro PS; Vilardell L; Solans M; Marcos-Gragera R. 2019. Clin Transl Oncol. 21(7): 891 - 899. IF:2,441.
Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients. Vera R; Otero MJ; Ayala de la Peña F; González-Pérez C; Peñuelas Á; Sepúlveda JM; Quer N; Doménech-Climent N; Virizuela JA; Beorlegui P; Gorgas MQ. 2019. Clin Transl Oncol. 21(4): 467 - 478. IF:2,441.
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). González Del Alba A; De Velasco G; Lainez N; Maroto P; Morales-Barrera R; Muñoz-Langa J; Pérez-Valderrama B; Basterretxea L; Caballero C; Vazquez S. 2019. Clin Transl Oncol. 21(1): 64 - 74. IF:2,441.
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). González-Flores E; Serrano R; Sevilla I; Viúdez A; Barriuso J; Benavent M; Capdevila J; Jimenez-Fonseca P; López C; Garcia-Carbonero R. 2019. Clin Transl Oncol. 21(1): 55 - 63. IF:2,441.
SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Chacón López-Muñiz JI; de la Cruz Merino L; Gavilá Gregori J; Martínez Dueñas E; Oliveira M; Seguí Palmer MA; Álvarez López I; Antolin Novoa S; Bellet Ezquerra M; López-Tarruella Cobo S. 2019. Clin Transl Oncol. 21(1): 31 - 45. IF:2,441.
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Carmona-Bayonas A; Jimenez-Fonseca P; de Castro EM; Mata E; Biosca M; Custodio A; Espinosa J; Vázquez EG; Henao F; Ayala de la Peña F. 2019. Clin Transl Oncol. 21(1): 75 - 86. IF:2,441.
The Medical Oncology resident mentor: situation and workload. Elez E; Quintanar T; Bosch-Barrera J; Corral J; Lainez N; Moreno V; Rodriguez CA; Gonzalez-Flores E; Cervantes A. 2019. Clin Transl Oncol. 21(3): 304 - 313. IF:2,441.
Lung cancer in Spanish women: The WORLD07 project. Garrido P; Viñolas N; Isla D; Provencio M; Majem M; Artal A; Carcereny E; Garcia Campelo R; Lianes P; De La Peñas R; Felip E. 2019. Eur J Cancer Care (Engl). 28(1): e12941. IF:2,421.
Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques. Gil-Moreno A; Carbonell-Socias M; Salicrú S; Centeno-Mediavilla C; Franco-Camps S; Colas E; Oaknin A; Pérez-Benavente A; Díaz-Feijoo B. 2019. J Minim Invasive Gynecol. 26(3): 492 - 500. IF:2,414.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer and brain metastases. Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Dieras V; Müller V; Tagliaferri M; Hannah AL; Cortés J. 2019. FUTURE ONCOL. 15(19): 2211 - 2225. IF:2,279.
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Sonbol MB; Ahn DH; Goldstein D; Okusaka T; Tabernero J; Macarulla T; Reni M; Li CP; O’Neil B; Cutsem EV; Bekaii-Saab T. 2019. FUTURE ONCOL. 15(12): 1295 - 1302. IF:2,279.
Could JAG1 protein inhibition prevent colorectal cancer? López-Arribillaga E; Rodilla V; Espinosa L. 2019. FUTURE ONCOL. 15(4): 345 - 347. IF:2,279.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R. 2019. FUTURE ONCOL. 15(17): 1951 - 1961. IF:2,279.
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Bang YJ; Van Cutsem E; Fuchs CS; Ohtsu A; Tabernero J; Ilson DH; Hyung WJ; Strong VE; Goetze TO; Yoshikawa T; Tang LH; Hwang PMT; Webb N; Adelberg D; Shitara K. 2019. FUTURE ONCOL. 15(9): 943 - 952. IF:2,279.
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Kato K; Shah MA; Enzinger P; Bennouna J; Shen L; Adenis A; Sun JM; Cho BC; Özgüroglu M; Kojima T; Kostorov V; Hierro C; Zhu Y; McLean LA; Shah S; Doi T. 2019. FUTURE ONCOL. 15(10): 1057 - 1066. IF:2,279.
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX. 2019. FUTURE ONCOL. 15(16): 1811 - 1822. IF:2,279.
The rise of oncology biosimilars: from process to promise. Verrill M; Declerck P; Loibl S; Lee J; Cortes J. 2019. FUTURE ONCOL. 15(28): 3255 - 3265. IF:2,279.
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Munster P; Mita M; Mahipal A; Nemunaitis J; Massard C; Mikkelsen T; Cruz C; Paz-Ares L; Hidalgo M; Rathkopf D; Blumenschein G; Smith DC; Eichhorst B; Cloughesy T; Filvaroff EH; Li S; Raymon H; de Haan H; Hege K; Bendell JC. 2019. Cancer Manag Res. 11: 10463 - 10476. IF:2,243.
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Sobas M; Rodriguez-Veiga R; Vellenga E; Paluszewska M; De la Serna J; García-Álvarez F; Gil C; Brunet S; Bergua J; González-Campos J; Ribera JM; Tormo M; González M; Fernández I; Benavente C; González-Sanmiguel JD; Esteve J; Pérez-Encinas M; Salamero O; Manso F; Lowenberg B; Sanzs MA; Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups. 2019. EUR J HAEMATOL. IF:2,217.
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C; Spanish group of blood and marrow transplantation (GETH). 2019. EUR J HAEMATOL. 102(6): 465 - 471. IF:2,217.
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. Barba P; Morgades M; Montesinos P; Gil C; Fox ML; Ciudad J; Moreno MJ; González-Campos J; Genescà E; Martínez-Carballeira D; Martino R; Vives S; Guardia R; Mercadal S; Artola MT; Cladera A; Tormo M; Esteve J; Bergua J; Vall-Llovera F; Ribera J; Martínez-Sanchez P; Amigo ML; Bermúdez A; Calbacho M; Hernández-Rivas JM; Feliu E; Orfao A; Ribera JM; PETHEMA Group. 2019. EUR J HAEMATOL. 102(1): 79 - 86. IF:2,217.
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. Jiménez-Segura R; Granell M; Gironella M; Abella E; García-Guiñón A; Oriol A; Cabezudo E; Clapés V; Soler JA; Escoda L; López-Pardo J; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Bladé J; Rosiñol L; GEMMAC (Grup per l l’estudi del mieloma mútiple i l’amiloïdosi de Catalunya). 2019. EUR J HAEMATOL. 102(5): 389 - 394. IF:2,217.
Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Vos JR; Giepmans L; Röhl C; Geverink N; Hoogerbrugge N; ERN GENTURIS. 2019. FAM CANCER. 18(2): 281 - 284. IF:2,209.
Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. Arce S; Athie A; Pritchard CC; Mateo J. 2019. ADV EXP MED BIOL. 1210: 279 - 300. IF:2,126.
A narrative overview of the patients’ outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling. Esteban I; Lopez-Fernandez A; Balmaña J. 2019. EUR J MED GENET. 62(5): 342 - 349. IF:2,022.
Cytokine release syndrome. Reviewing a new entity in the intensive care unit. Roche AG; Lagares CD; Élez E; Roca RF. 2019. MED INTENSIVA. 43(8): 480 - 488. IF:1,982.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA. 2019. Int J Gynecol Cancer. 29(9): 1396 - 1404. IF:1,746.
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A. 2019. J Comp Eff Res. 8(3): 165 - 178. IF:1,485.
Allogeneic stem cell transplantationin the era of novel therapies for acute lymphoblastic leukaemia. Barba P; Elorza I. 2019. Med Clin (Barc). 153(1): 28 - 34. IF:1,277.
Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjogren’s syndrome: which associated condition should be prioritized? Pardos-Gea J; Martínez F; Abrisqueta P; Santamaría A; Bosch F. 2019. Blood Coagul Fibrinolysis. 30(5): 239 - 242. IF:1,120.
Articles published by VHIO Investigators in 2019 in journals with no Impact Factor (IF) allocated at the time of publication of this Scientific Report:
“The TEAM Project” Results on Management of Placenta-Mediated Pregnancy Complications (PMC): The Impact of Thrombophilia Test and Thromboprophylaxis with Low-Molecular-Weight-Heparin on Recurrences of PMC. Santamaria A; Martí E; Medina C; Rodríguez AM; Stevenazzi M; Mira Y; López M; Redondo AM; Aguinaco R; Sabater MC; Oliver A. 2019. J Blood Lymph. 9(2).
Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations. Tabernero J. 2019. ESMO Open. 4(1): UNSP e000494.
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. Cejalvo JM; Jacob W; Fleitas Kanonnikoff T; Felip E; Navarro Mendivil A; Martinez Garcia M; Taus Garcia A; Leighl N; Lassen U; Mau-Soerensen M; Adessi C; Michielin F; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A. 2019. ESMO Open. 4(4): UNSP e000532.
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? Pellegrino B; Mateo J; Serra V; Balmaña J. 2019. ESMO Open. 4(2): UNSP e000480.
Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer. Alsina M; Smyth EC. 2019. ESMO Open. 4(5): UNSP e000591.
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. Rodriguez-Freixinos V; Ruiz-Pace F; Fariñas-Madrid L; Garrido-Castro AC; Villacampa G; Nuciforo P; Vivancos A; Dienstmann R; Oaknin A. 2019. ESMO Open. 4(2): UNSP e000444.
Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. Lordick F; Obermannova R; Vola D; Douillard JY; Mcgregor K; Van Cutsem E; Tabernero J; Ciardiello F; Cervantes A. 2019. ESMO Open. 4(3): UNSP e000533.
How I treat gastric adenocarcinoma. Alsina M; Miquel JM; Diez M; Castro S; Tabernero J. 2019. ESMO Open. 4: UNSP e000521.
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. Giuliani R; Tabernero J; Cardoso F; McGregor KH; Vyas M; de Vries EGE. 2019. ESMO Open. 4(2): UNSP e000460.
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Mohr P; Kiecker F; Soriano V; Dereure O; Mujika K; Saiag P; Utikal J; Koneru R; Robert C; Cuadros F; Chacón M; Villarroel RU; Najjar YG; Kottschade L; Couselo EM; Koruth R; Guérin A; Burne R; Ionescu-Ittu R; Perrinjaquet M; Zager JS. 2019. Melanoma Manag. 6(4): MMT33.
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; Jiménez JL; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Rodriguez A; Lorza L; Martín A; Coria E; López-Guillermo A; Salar A; José Lahuerta J; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu. 2019. Hematol Oncol Stem Cell Ther. 12(4): 194 - 203.
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists. Sanchez-Rovira P; Zamora P; Salvador-Bofill J; Morales S; Martinez-Janez N; Martinez-de-Duenas E; Lluch A; Juan Illarramendi J; Gomez-Pardo P; Gavila Gregori J; Garcia-Palomo A; Garcia-Mata J; Fernandez Y; del Barco S; de Juan Ana; Ciruelos E; Ignacio Chacon J; Calvo L; Barnadas A; Albanell J. 2019. Journal Of Drug Assessment. 8(1): 62 - 69.
Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B. Rosso M; Lapyckyj L; Besso MJ; Monge M; Reventós J; Canals F; Quevedo Cuenca JO; Matos ML; Vazquez-Levin MH. 2019. Cancer Metab. 7: 5 - 5.
Detection of pancreatic neuroendocrine tumors: 23 years of experience. Varas-Lorenzo MJ; Cugat E; Capdevila J; Sánchez-Vizcaíno Mengual E. 2019. Rev Gastroenterol Mex. 84(1): 18 - 25.
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. Burzykowski T; Coart E; Saad ED; Sommeijer DW; Bokemeyer C; Hurwitz H; Kabbinavar FF; Koopman M; Adam R; Adams R; Ajani J; Allegra CJ; Andre T; Arnold D; Bachet J-B; Benson AB; Berlin J; Bleiberg H; Bodoky G; Buyse M; Chibaudel B; Diaz-Rubio E; Douillard J-Y; Ellis L; Eng C; Falcone A; Franko J; Fuchs CS; Fujii M; Giantonio BJ; Goldberg RM; de Gramont A; Grothey A; Haller D; Hamilton SR; Hausner PF; Hecht JR; Heinemann V; Herrera A; Hochster HS; Hoff PM; Jonker DJ; Kaplan R; Koeberle D; Kopetz S; Labianca RF; Larsen AK; Lenz H-J; Lieu C; Louvet C; Loupakis F; Marshall J; Maughan TS; Mayer RJ; Meropol NJ; Mitchell EP; O’Connell MJ; Peeters M; Porschen R; Price T; Punt CJA; Salem ME; Saltz L; Schilsky R; Schmoll HJ; Seymour MT; Shmueli ES; Shi Q; Sobrero A; Souglakos J; Tabernero J; et al. 2019. Jama Network Open. 2(9): e1911750.
Finding MYCure. Beaulieu ME; Soucek L. 2019. Mol Cell Oncol. 6(5): e1618178.
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Michels S; Heydt C; van Veggel B; Deschler-Baier B; Pardo N; Monkhorst K; Ruesseler V; Stratmann J; Griesinger F; Steinhauser S; Kostenko A; Diebold J; Fassunke J; Fischer R; Engel-Riedel W; Gautschi O; Geissinger E; Haneder S; Ihle MA; Kopp H-G; de Langen AJ; Martinez-Marti A; Nogova L; Persigehl T; Plenker D; Puesken M; Rodermann E; Rosenwald A; Scheel AH; Scheffler M; Spengler W; Seggewiss-Bernhardt R; Braegelmann J; Sebastian M; Vrugt B; Hellmich M; Sos ML; Heukamp LC; Felip E; et al. 2019. JCO Precis Oncol. 3.
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. Subbiah V; Gervais R; Riely G; Hollebecque A; Blay J-Y; Felip E; Schuler M; Goncalves A; Italiano A; Keedy V; Chau I; Puzanov, I; Raje NS; Meric-Bernstam F; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM. 2019. JCO Precis Oncol. 3.
RNF43 - and NOTCH1 -Mutated Chemotherapy and Anti–EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies? Aguilar S; Santos C; Martini G; Argiles G; Azaro A; Garralda E; Tabernero J; Nuciforo P; Vivancos A; Dienstmann R. 2019. JCO Precis Oncol. 1 - 3.
Selection of Radiomics Features based on their Reproducibility. Ligero M; Torres G; Sanchez C; Diaz-Chito K; Perez R; Gil D. 2019. Conf Proc IEEE Eng Med Biol Soc. 2019: 403 - 408.
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Figlioli G; Bogliolo M; Catucci I; Caleca L; Lasheras SV; Pujol R; Kiiski JI; Muranen TA; Barnes DR; Dennis J; Michailidou K; Bolla MK; Leslie G; Aalfs CM; ABCTB Investigators; Adank MA; Adlard J; Agata S; Cadoo K; Agnarsson BA; Ahearn T; Aittomäki K; Ambrosone CB; Andrews L; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Arun BK; Asseryanis E; Auber B; Auvinen P; Azzollini J; Balmaña J; et al. 2019. NPJ Breast Cancer. 5: 38 - 38.
Thrombosis and hemostasis health in pregnancy: Registries from the International Society on Thrombosis and Haemostasis. Othman M; Santamaría Ortiz A; Cerdá M; Erez O; Minford A; Obeng-Tuudah D; Blondon M; Bistervels I; Middeldorp S; Abdul-Kadir R. 2019. Res Pract Thromb Haemost. 3(4): 607 - 614.
Selection of some of the most relevant articles by VHIO researchers
Below is a selected list of articles published by VHIO researchers in 2019 with respective Impact Factors indicated.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D; CARD Investigators. 2019. N Engl J Med. 381(26): 2506 - 2518. IF:70,670.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Kappeler C; Snapir A; Sarapohja T; Smith MR; ARAMIS Investigators. 2019. N Engl J Med. 380(13): 1235 - 1246. IF:70,670.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J. 2019. N Engl J Med. 381(17): 1632 - 1643. IF:70,670.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O’Hagan A; Avadhani A; Siefker-Radtke AO; BLC2001 Study Group. 2019. N Engl J Med. 381(4): 338 - 348. IF:70,670.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O’Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL. 2019. N Engl J Med. 381(4): 317 - 327. IF:70,670.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O’Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. 2019. N Engl J Med. 381(25): 2391 - 2402. IF:70,670.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA. 2019. N Engl J Med. 381(25): 2403 - 2415. IF:70,670.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ; IMmotion151 Study Group. 2019. Lancet. 393(10189): 2404 - 2415. IF:59,102.
Cervical cancer. Cohen PA; Jhingran A; Oaknin A; Denny L. 2019. Lancet. 393(10167): 169 - 182. IF:59,102.
Actively personalized vaccination trial for newly diagnosed glioblastoma. Hilf N; Kuttruff-Coqui S; Frenzel K; Bukur V; Stevanovic S; Gouttefangeas C; Platten M; Tabatabai G; Dutoit V; van der Burg SH; Thor Straten P; Martínez-Ricarte F; Ponsati B; Okada H; Lassen U; Admon A; Ottensmeier CH; Ulges A; Kreiter S; von Deimling A; Skardelly M; Migliorini D; Kroep JR; Idorn M; Rodon J; et al. 2019. Nature. 565(7738): 240 - 245. IF:43,070.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F; IMblaze370 Investigators. 2019. Lancet Oncol. 20(6): 849 - 861. IF:35,386.
ESMO-MCBS: setting the record straight. Cherny NI; Tabernero J; de Vries EGE. 2019. Lancet Oncol. 20(4): 192 - 192. IF:35,386.
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2-3, randomised, controlled trial. Bonvalot S; Rutkowski PL; Thariat J; Carrère S; Ducassou A; Sunyach MP; Agoston P; Hong A; Mervoyer A; Rastrelli M; Moreno V; Li RK; Tiangco B; Herraez AC; Gronchi A; Mangel L; Sy-Ortin T; Hohenberger P; de Baère T; Le Cesne A; Helfre S; Saada-Bouzid E; Borkowska A; Anghel R; Co A; Gebhart M; Kantor G; Montero A; Loong HH; Vergés R; et al... 2019. Lancet Oncol. 20(8): 1148 - 1159. IF:35,386.
PET or MRI to improve response evaluation in clinical trials? Deroose CM; Gheysens O; Perez-Lopez R. 2019. Lancet Oncol. 20(8): 1060 - 1062. IF:35,386.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I. 2019. Lancet Oncol. 20(8): 1109 - 1123. IF:35,386.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA; RAINFALL Study Group. 2019. Lancet Oncol. 20(3): 420 - 435. IF:35,386.
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M. 2019. Lancet Oncol. 20(10): 1454 - 1466. IF: 35,386.
Shortages of inexpensive essential medicines. Vyas M; de Vries EGE; Casali PG; Tabernero J. 2019. Lancet Oncol. 20(5): 224 - 225. IF:35,386.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E. 2019. Lancet Oncol. 20(9): 1226 - 1238. IF:35,386.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P. 2019. Lancet Oncol. 20(8): 1124 - 1135. IF:35,386.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Vergote I; Scambia G; O’Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. 2019. Lancet Oncol. 20(6): 862 - 876. IF:35,386.
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F. 2019. Lancet Oncol. 20(12): 1702 - 1709. IF:35,386.
Chronic lymphocytic leukaemia: from genetics to treatment. Bosch F; Dalla-Favera R. 2019. Nat Rev Clin Oncol. 16(11): 684 - 701. IF:34,106.
Breast cancer. Harbeck N; Penault-Llorca F; Cortes J; Gnant M; Houssami N; Poortmans P; Ruddy K; Tsang J; Cardoso F. 2019. Nat Rev Dis Primers. 5: 66. IF:32,274.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Powles T; Kockx M; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Szabados B; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; van Dam PJ; Stanoeva D; Daelemans S; Mariathasan S; Tea JS; Mousa K; Banchereau R; Castellano D. 2019. Nat Med. 25(11): 1706 - 1706. IF:30,641.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Rodon J; Soria JC; Berger R; Miller WH; Rubin E; Kugel A; Tsimberidou A; Saintigny P; Ackerstein A; Braña I; Loriot Y; Afshar M; Miller V; Wunder F; Bresson C; Martini JF; Raynaud J; Mendelsohn J; Batist G; Onn A; Tabernero J; Schilsky RL; Lazar V; Lee JJ; Kurzrock R. 2019. Nat Med. 25(5): 751 - 751. IF:30,641.
Looking forward 25 years: the future of medicine. Regev A; Zhang F; Jaffee E; Farrar J; Nkengasong J; Topol E; Partridge L; Mundel T; Tabernero J; Sabeti P; Torreele E. 2019. Nat Med. 25(12): 1804 - 1807. IF:30,641.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF. 2019. J Clin Oncol. 37(16): 1370 - 1370. IF:28,349.
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J. 2019. J Clin Oncol. 37(17): 1460 - 1460. IF:28,349.
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL. 2019. J Clin Oncol. 37(4): 336 - 336. IF:28,349.
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R. 2019. J Clin Oncol. 37(28): 2518 - 2518. IF:28,349.
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. Fennell D A; Baas P; Taylor P; Nowak A K; Gilligan D; Nakano T; Pachter J A; Weaver D T; Scherpereel A; Pavlakis N; van Meerbeeck J P; Cedres S; Nolan L; Kindler H; Aerts J G J V. 2019. J Clin Oncol. 37(10): 790 - 790. IF:28,349.
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ. 2019. J Clin Oncol. 37(25): 2257 - 2257. IF:28,349.
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G. 2019. J Clin Oncol. 37(5): 367 - 367. IF:28,349.
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M. 2019. J Clin Oncol. 37(3): 230 - 230. IF:28,349.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Gulley JL; Borre M; Vogelzang NJ; Ng S; Agarwal N; Parker CC; Pook DW; Rathenborg P; Flaig TW; Carles J; Saad F; Shore ND; Chen L; Heery CR; Gerritsen WR; Priou F; Langkilde NC; Novikov A; Kantoff PW. 2019. J Clin Oncol. 37(13): 1051 - 1051. IF:28,349.
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R. 2019. J Clin Oncol. 37(28): 2571 - 2571. IF:28,349.
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; et al. 2019. J Clin Oncol. 37(6): 490 - 490. IF:28,349.
Reply to I. Pecora et al. Macarulla T; Hidalgo M. 2019. J Clin Oncol. 37(22): 1979 - 1979. IF:28,349.
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN. 2019. J Clin Oncol. 37(31): 2825 - 2825. IF:28,349.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O’Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM. 2019. Cancer Discov. 9(2): 210 - 219. IF:26,370.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; et al. 2019. Cancer Discov. 9(12): 1696 - 1707. IF:26,370.
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 + T Cells. Etxeberria I; Bolaños E; Quetglas JI; Gros A; Villanueva A; Palomero J; Sánchez-Paulete AR; Piulats JM; Matias-Guiu X; Olivera I; Ochoa MC; Labiano S; Garasa S; Rodriguez I; Vidal A; Mancheño U; Hervás-Stubbs S; Azpilikueta A; Otano I; Aznar MA; Sanmamed MF; Inogés S; Berraondo P; Teijeira Á; Melero I. 2019. Cancer Cell. 36(6): 613 - 613. IF:23,916.
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS. 2019. Lancet Respir Med. 7(7): 569 - 580. IF:22,992.
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leigh N B; Hellmann M D; Hui R; Carcereny E; Felip E; Ahn M-J; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB. 2019. Lancet Respir Med. 7(4): 347 - 357. IF:22,992.
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial. Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS. 2019. JAMA Oncol. 5(2): e184475. IF:22,416.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. Fernández-Martos C; Pericay C; Losa F; García-Carbonero R; Layos L; Rodríguez-Salas N; Martin-Richard M; Alonso-Orduña V; Vera R; Gallego J; Capdevila J; Salud A; Nogué M; Maurel J; Guash I; Montagut C; Lopez C; Macias I; Jain RK; Garcia-Albeniz X. 2019. JAMA Oncol. 5(11): 1566 - 1573. IF:22,416.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer The MANTA Phase 2 Randomized Clinical Trial. Schmid P; Zaiss M; Harper-Wynne C; Ferreira M; Dubey S; Chan S; Makris A; Nemsadze G; Brunt AM; Kuemmel S; Ruiz I; Perelló A; Kendall A; Brown J; Kristeleit H; Conibear J; Saura C; Grenier J; Máhr K; Schenker M; Sohn J; Lee KS; Shepherd CJ; Oelmann E; Sarker SJ; Prendergast A; Marosics P; Moosa A; Lawrence C; Coetzee C; Mousa K; Cortés J. 2019. JAMA Oncol. 5(11): 1556 - 1563. IF:22,416.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study. Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O’Hear C; Fassò M; Molinero L; Schmid P. 2019. JAMA Oncol. 5(1): 74 - 82. IF:22,416.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial. Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J. 2019. JAMA Oncol. 5(2): 195 - 203. IF:22,416.
Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? Riveiro-Barciela M; Muñoz-Couselo E; Fernandez-Sojo J; Diaz-Mejia N; Parra-López R; Buti M. 2019. J HEPATOL. 70(3): 564 - 566. IF:18,946.
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Janin M; Ortiz-Barahona V; de Moura MC; Martínez-Cardús A; Llinàs-Arias P; Soler M; Nachmani D; Pelletier J; Schumann U; Calleja-Cervantes ME; Moran S; Guil S; Bueno-Costa A; Piñeyro D; Perez-Salvia M; Rosselló-Tortella M; Piqué L; Bech-Serra JJ; De La Torre C; Vidal A; Martínez-Iniesta M; Martín-Tejera JF; Villanueva A; Arias A; Cuartas I; Aransay AM; La Madrid AM; Carcaboso AM; Santa-Maria V; Mora J; Fernandez AF; Fraga MF; Aldecoa I; Pedrosa L; Graus F; Vidal N; Martínez-Soler F; Tortosa A; Carrato C; Balañá C; Boudreau MW; Hergenrother PJ; Kötter P; Entian KD; Hench J; Frank S; Mansouri S; Zadeh G; Dans PD; Orozco M; Thomas G; Blanco S; Seoane J; et al. 2019. ACTA NEUROPATHOL. 138(6): 1053 - 1074. IF:18,174.
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS. 2019. EUR UROL. 76(5): 676 - 685. IF:17,298.
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Zafeiriou Z; Bianchini D; Chandler R; Rescigno P; Yuan W; Carreira S; Barrero M; Petremolo A; Miranda S; Riisnaes R; Rodrigues DN; Gurel B; Sumanasuriya S; Paschalis A; Sharp A; Mateo J; Tunariu N; Chinnaiyan AM; Pritchard CC; Kelly K; de Bono JS. 2019. EUR UROL. 75(1): 184 - 192. IF:17,298.
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O’Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; et al. 2019. EUR UROL. 76(6): 831 - 842. IF:17,298.
Managing Nonmetastatic Castration-resistant Prostate Cancer. Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS. 2019. EUR UROL. 75(2): 285 - 293. IF:17,298.
PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. Mateo J; Carreira S; de Bono JS. 2019. EUR UROL. 76(4): 459 - 460. IF:17,298.
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; et al. 2019. EUR UROL. 75(3): 368 - 373. IF:17,298.
Towards a New Classification for Metastatic Prostate Cancer. Mateo J; Carles J. 2019. EUR UROL. 75(3): 383 - 384. IF:17,298.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L. 2019. Sci Transl Med. 11(484): eaar5012. IF:17,200.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J. 2019. Blood. 134(16): 1337 - 1345. IF:16,601.
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; NguyenKhac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; et al. 2019. Blood. 133(11): 1205 - 1216. IF:16,601.
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Schuster SJ; Bartlett NL; Assouline S; Yoon S-S; Bosch F; Sehn LH; Cheah CY; Shadman M; Gregory G P; Ku M; Wei MC; Yin S; Kwan A; Yousefi K; Hernandez G; Li C-C; O’Hear C; Budde LE. 2019. Blood. 134(1): 6 - 6. IF:16,601.
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Garmendia I; Pajares M J; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba I I; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga L M; Agorreta J. 2019. Am J Respir Crit Care Med. 200(7): 888 - 899. IF:16,494.
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Pesarrodona M; Jauset T; Díaz-Riascos ZV; Sánchez-Chardi A; Beaulieu ME; Seras-Franzoso J; Sánchez-García L; Baltà-Foix R; Mancilla S; Fernández Y; Rinas U; Schwartz S; Soucek L; Villaverde A; Abasolo I; Vázquez E. 2019. Adv Sci (Weinh). 6(18): 1900849 - 1900849. IF:15,804.
Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory? Riveiro-Barciela M; Gironella M; Senín A; Salcedo MT; Merino-Casabiel X; Castells L; Esteban R; Buti M; Martínez-Valle F. 2019. Hepatology. 69(6): 2701 - 2703. IF:14,971.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer. Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R. 2019. Ann Oncol. 30(6): 927 - 933. IF:14,196.
A decade of clinical development of PARP inhibitors in perspective. Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS. 2019. Ann Oncol. 30(9): 1437 - 1447. IF:14,196.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Matulonis UA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Katchar K; Wu H; Keefe S; Ruman J; Ledermann JA. 2019. Ann Oncol. 30(7): 1080 - 1087. IF:14,196.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner N C; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M. 2019. Ann Oncol. 30(5): 774 - 780. IF:14,196.
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Yoshino T; Portnoy DC; Obermannová R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; García-Alfonso P; Cohn AL; Van Cutsem E; Yamazaki K; Lonardi S; Muro K; Kim TW; Yamaguchi K; Grothey A; O’Connor J; Taieb J; Wijayawardana SR; Hozak RR; Nasroulah F; Tabernero J. 2019. Ann Oncol. 30(1): 124 - 131. IF:14,196.
Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Seoane J; De Mattos-Arruda L; Le Rhun E; Bardelli A; Weller M. 2019. Ann Oncol. 30(2): 211 - 218. IF:14,196.
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L. 2019. Ann Oncol. 30(2): 290 - 296. IF:14,196.
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner NC. 2019. Ann Oncol. 30(6): 945 - 952. IF:14,196.
Efficacy of PI3K inhibitors in advanced breast cancer. Verret B; Cortes J; Bachelot T; Andre F; Arnedos M. 2019. Ann Oncol. Dec;30 Suppl 10:x12-x20. IF:14,196.
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ. 2019. Ann Oncol. 30(8): 1289 - 1297. IF:14,196.
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC. 2019. Ann Oncol. 30(3): 365 - 373. IF:14,196.
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Hammel P; Kindler HL; Reni M; Cutsem EV; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O’Reilly EM; McGuinness D; Cui K Y; Joo S; Yoo HK; Patel N; Golan T. 2019. Ann Oncol. 30(12): 1959 - 1968. IF:14,196.
Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N; Moreira L; Carneiro F; Balaguer F; Cervantes A; Balmaña J; Martinelli E. 2019. Ann Oncol. 30(10): 1558 - 1571. IF:14,196.
How liquid biopsies can change clinical practice in oncology. Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu L L; Bardelli A. 2019. Ann Oncol. 30(10): 1580 - 1590. IF:14,196.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazières J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai A A; Mascaux C; Couraud S; Veillon R; Van Den Heuvel M; Neal J; Peled N; Früh M; Ng T L; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez A; et al. 2019. Ann Oncol. 30(8): 1321 - 1328. IF:14,196.
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. Ros J; Matos I; Martin-Liberal J. 2019. Ann Oncol. 30(7): 1173 - 1177. IF:14,196.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K; Van Cutsem E; Narita Y; Pentheroudakis G; Baba E; Li J; Ryu MH; Zamaniah WIW; Yong WP; Yeh KH; Kato K; Lu Z; Cho B C; Nor I M; Ng M; Chen LT; Nakajima TE; Shitara K; Kawakami H; Tsushima T; Yoshino T; Lordick F; Martinelli E; Smyth EC; Arnold D; Minami H; Tabernero J; Douillard JY. 2019. Ann Oncol. 30(1): 19 - 33. IF:14,196.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K; Lordick F; Tsushima T; Pentheroudakis G; Baba E; Lu Z; Cho BC; Nor IM; Ng M; Chen LT; Kato K; Li J; Ryu MH; Zamaniah WIW; Yong WP; Yeh KH; Nakajima TE; Shitara K; Kawakami H; Narita Y; Yoshino T; Van Cutsem E; Martinelli E; Smyth EC; Arnold D; Minami H; Tabernero J; Douillard JY. 2019. Ann Oncol. 30(1): 34 - 43. IF:14,196.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Adams S; Schmid P; Rugo HS; Winer EP; Loirat D; Awada A; Cescon DW; Iwata H; Campone M; Nanda R; Hui R; Curigliano G; Toppmeyer D; O’Shaughnessy J; Loi S; Paluch-Shimon S; Tan AR; Card D; Zhao J; Karantza V; Cortés J. 2019. Ann Oncol. 30(3): 397 - 404. IF:14,196.
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E. 2019. Ann Oncol. 30(5): 796 - 803. IF:14,196.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Peters S; Dafni U; Boyer M; De Ruysscher D; Faivre-Finn C; Felip E; Garrido P; Girard N; Guckenberger M; Haanen J; Le Pechoux C; Mornex F; Ozsahin M; Paz-Ares L; Planchard D; Raben D; Ramalingam S; Reck M; Smit E; Stahel R; Stenzinger A; Swanton C; Vallone S; Garassino MC. 2019. Ann Oncol. 30(2): 161 - 165. IF:14,196.
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Sveen A; Cremolini C; Dienstmann R. 2019. Ann Oncol. 30(11): 1682 - 1685. IF:14,196.
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J. 2019. Ann Oncol. 30(10): 1622 - 1629. IF:14,196.
Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager? Saura C. 2019. Ann Oncol. 30(10): 1 - 2. IF:14,196.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Serrano C; Cortés J; De Mattos-Arruda L; Bellet M; Gómez P; Saura C; Pérez J; Vidal M; Muñoz-Couselo E; Carreras MJ; Sánchez-Ollé G; Tabernero J; Baselga J; Di Cosimo S. 2019. Ann Oncol. 30(7): 1178 - 1178. IF:14,196.
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C. 2019. Ann Oncol. 30(3): 439 - 446. IF:14,196.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB. 2019. Ann Oncol. 30(2): 281 - 289. IF:14,196.
Value assessment frameworks in oncology: championing concordance through shared standards. Bertagnolli M; Tabernero J. 2019. Ann Oncol. 30(4): 505 - 506. IF:14,196.
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Remon J; Ahn MJ; Girard N; Johnson M; Kim DW; Lopes G; Pillai RN; Solomon B; Villacampa G; Zhou Q. 2019. J Thorac Oncol. 14(7): 1134 - 1155. IF:12,460.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasag B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S. 2019. J Thorac Oncol. 14(6): 1086 - 1094. IF:12,460.
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; et al. 2019. J Thorac Oncol. 14(12): 2120 - 2132. IF:12,460.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS. 2019. J Thorac Oncol. 14(5): 793 - 801. IF:12,460.
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH J r, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. 2019. J Thorac Oncol. Epub 2019 Dec 20. PMID: 31870883. IF:12,460.
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer. Bauer TM; Besse B; Martinez-Marti A; Trigo JM; Moreno V; Garrido P; Ferron-Brady G; Wu Y; Park J; Collingwood T; Kruger RG; Mohammad HP; Ballas MS; Dhar A; Govindan R. 2019. J Thorac Oncol. 14(10): 1828 - 1838. IF:12,460.
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; et al. 2019. J Thorac Oncol. 14(7): 1266 - 1276. IF:12,460.
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA. 2019. J Clin Invest. 129(11): 4992 - 5004. IF:12,282.
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D; EINSTEIN-Jr Phase 2 Investigators. 2019. Lancet Haematol. 6(10): 500 - 509. IF:11,990.
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yagci M; et al. 2019. Lancet Haematol. 6(2): 67 - 78. IF:11,990.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Wang Y; Bernhardy AJ; Nacson J; Krais JJ; Tan Y F; Nicolas E; Radke MR; Handorf E; Llop-Guevara A; Balmaña J; Swisher EM; Serra V; Peri S; Johnson N. 2019. Nat Commun. 10: 5661 - 5661. IF:11,878.
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Ferreira MA; Gamazon ER; Al-Ejeh F; Aittomäki K; Andrulis IL; Anton-Culver H; Arason A; Arndt V; Aronson KJ; Arun BK; Asseryanis E; Azzollini J; Balmaña J; Barnes DR; Barrowdale D; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bialkowska K; Blomqvist C; Bogdanova NV; Bojesen SE; Bolla MK; Borg A; Brauch H; Brenner H; Broeks A; Burwinkel B; Caldés T; Caligo MA; Campa D; Campbell I; Canzian F; Carter J; Carter BD; Castelao JE; Chang-Claude J; Chanock SJ; Christiansen H; Chung WK; Claes KBM; Clarke CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; de la Hoya M; Dennis J; Devilee P; Diez O; et al. 2019. Nat Commun. 10(1): 1741 - 1741. IF:11,878.
Identification and characterization of Cardiac Glycosides as senolytic compounds. Triana-Martínez F; Picallos-Rabina P; Da Silva-Álvarez S; Pietrocola F; Llanos S; Rodilla V; Soprano E; Pedrosa P; Ferreirós A; Barradas M; Hernández-González F; Lalinde M; Prats N; Bernadó C; González P; Gómez M; Ikonomopoulou MP; Fernández-Marcos PJ; García-Caballero T; Del Pino P; Arribas J; Vidal A; González-Barcia M; Serrano M; Loza MI; Domínguez E; Collado M. 2019. Nat Commun. 10(1): 4731 - 4731. IF:11,878.
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Pascual-García M; Bonfill-Teixidor E; Planas-Rigol E; Rubio-Perez C; Iurlaro R; Arias A; Cuartas I; Sala-Hojman A; Escudero L; Martínez-Ricarte F; Huber-Ruano I; Nuciforo P; Pedrosa L; Marques C; Braña I; Garralda E; Vieito M; Squatrito M; Pineda E; Graus F; Espejo C; Sahuquillo J; Tabernero J; Seoane J. 2019. Nat Commun. 10: 2416 - 2416. IF:11,878.
Shared heritability and functional enrichment across six solid cancers. Jiang X; Finucane HK; Schumacher FR; Schmit SL; Tyrer JP; Han Y; Michailidou K; Lesseur C; Kuchenbaecker KB; Dennis J; Conti DV; Casey G; Gaudet MM; Huyghe JR; Albanes D; Aldrich MC; Andrew AS; Andrulis IL; Anton-Culver H; Antoniou AC; Antonenkova NN; Arnold SM; Aronson KJ; Arun BK; Bandera EV; Barkardottir RB; Barnes DR; Batra J; Beckmann MW; Benitez J; Benlloch S; Berchuck A; Berndt SI; Bickeböller H; Bien SA; Blomqvist C; Boccia S; Bogdanova NV; Bojesen SE; Bolla MK; Brauch H; Brenner H; Brenton JD; Brook MN; Brunet J; Brunnström H; Buchanan DD; Burwinkel B; Butzow R; Cadoni G; Caldés T; Caligo MA; Campbell I; Campbell PT; Cancel-Tassin G; Cannon-Albright L; Campa D; Caporaso N; Carvalho AL; Chan AT; Chang-Claude J; Chanock SJ; Chen C; Christiani DC; Claes KBM; Claessens F; Clements J; Collée JM; Correa MC; Couch FJ; Cox A; Cunningham JM; Cybulski C; Czene K; Daly MB; deFazio A; Devilee P; Diez O; et al. 2019. Nat Commun. 10(1): 431 - 431. IF:11,878.
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Gao M; Callari M; Beddowes E; Sammut SJ; Grzelak M; Biggs H; Jones L; Boumertit A; Linn SC; Cortes J; Oliveira M; Baird R; Chin SF; Caldas C. 2019. Genome Med. 11(1): 1 - 1. IF:10,886.
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Qian F; Wang S; Mitchell J; McGuffog L; Barrowdale D; Leslie G; Oosterwijk JC; Chung WK; Evans DG; Engel C; Kast K; Aalfs CM; Adank MA; Adlard J; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Arun BK; Ausems MGEM; Azzollini J; Barouk-Simonet E; Barwell J; Belotti M; Benitez J; Berger A; Borg A; Bradbury AR; Brunet J; Buys SS; Caldes T; Caligo MA; Campbell I; Caputo SM; Chiquette J; Claes KBM; Margriet Collée J; Couch FJ; Coupier I; Daly MB; Davidson R; Diez O; et al. 2019. J Natl Cancer Inst. 111(4): 350 - 364. IF:10,211.
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Ignatiadis M; Van den Eynden G; Roberto S; Fornili M; Bareche Y; Desmedt C; Rothé F; Maetens M; Venet D; Holgado E; McNally V; Kiermaier A; Savage HM; Wilson TR; Cortes J; Schneeweiss A; Willard-Gallo K; Biganzoli E; Sotiriou C. 2019. J Natl Cancer Inst. 111(1): 69 - 77. IF:10,211.
Scientific productivity: research articles
Articles published in 2019
In 2019, 333 scientific articles were published by VHIO researchers as corresponding/senior or co-authors with a cumulative Impact Factor (IF) totaling at 3806 and a Median Impact Factor (MIF) of 11,43. These figures reflect both the scientific impact and importance of VHIO's research and contributions to the oncology field:
Figure I
Number of articles published by VHIO researchers from 2007 - 2019

Figure II
Median Impact Factor of papers published by VHIO faculty from 2007 - 2019
